

PCT/GB2004/5140
GB04/05140



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Andrew Gersey

Dated

31 December 2004

BEST AVAILABLE COPY



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales

23SEP04 E928001-4 000010.8QQ
P01/7700 0.00-0421110.8 ACCOUNT CHA

1. Your reference

P038854GB

2. Patent application number

(The Patent Office will fill this part in)

0421110.8

3. Full name, address and postcode of the or of each applicant (underline all surnames)

OXFORD GENE TECHNOLOGY IP LIMITED
Begbroke Business & Science Park
Hirsch Building
Sandy Lane, Yarnton
Oxford
OX5 1PF

Patents ADP number (if you know it)

8734717001

If the applicant is a corporate body, give the country/state of its incorporation

GB

4. Title of the invention

DERIVATISED MOLECULES FOR MASS SPECTROMETRY

5. Name of your agent (if you have one)

CARPMAELS & RANSFORD

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

43-45 BLOOMSBURY SQUARE
LONDON WC1A 2RA
GB

Patents ADP number (if you know it)

83001✓

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

YES

Otherwise answer NO (See note d)

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form. -

Description	54
Claim(s)	11
Abstract	0
Drawing(s)	15 + 15

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77)

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

CARPMAELS & RANSFORD

Date 22 Sept 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

CAMERON MARSHALL

020 7242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

DERIVATISED MOLECULES FOR MASS SPECTROMETRY

All documents cited herein are incorporated by reference in their entirety.

TECHNICAL FIELD

This invention relates to derivatised biopolymers and ions obtainable therefrom. The invention
5 further relates to compounds and solid supports useful for producing the derivatised biopolymers and ions of the invention.

BACKGROUND OF THE INVENTION

Mass spectrometry is a versatile analytical technique possessing excellent detection range and speed
of detection with respect to High Performance Liquid Chromatography (HPLC), Gas
10 Chromatography (GC), Infra-Red (IR) and Nuclear Magnetic Resonance (NMR).

However, many biopolymers, such as carbohydrates and proteins, are difficult to analyse using mass
spectrometry due to significant difficulties in ionising the biopolymer, even using Matrix Assisted
Laser Desorption/Ionisation Time Of Flight (MALDI-TOF) techniques. Despite the considerable
resolving power of 2D-PAGE, this technology has fallen far short of the ultimate goal of displaying
15 the whole proteome in a single experiment, as many proteins are resistance to 2D-PAGE analysis (*e.g.*
those with low or high molecular masses, membrane proteins, proteins with extreme isoelectric
points, *etc.*). Many proteins are thus invisible to 2-D PAGE [Cravatt & Sorensen (2000) Current
Opinion in Chemical Biology vol. 4, p. 663-668].

There is thus a need for improvements in mass spectrometry analysis of biopolymers.

20 DISCLOSURE OF THE INVENTION


It has now been found that covalent attachment of trityl derivatives to biopolymers can improve the
ionisation properties of the biopolymer. The ions (formula (I) below) formed by ionisation of the
derivatised biopolymers are particularly suitable for mass spectrometry analysis, and biopolymers
derivatised as specified in formulae (IIIa) and (IIIb) below can be readily ionised.

25 Whereas triphenylmethyl derivatives covalently attached to certain biopolymers (*e.g.* DNA) are
known in the prior art [*e.g.* Chem. Soc. Rev. (2003) 32, p. 3-13], the prior art attaches the polymer to
the α -triphenylmethyl carbon atom through a non-aromatic linker. In contrast, under the present
invention the biopolymer is attached to the α -triarylmethyl carbon atom via an aromatic group
adjacent to the central carbon atom. Consequently, ionisation of the prior art derivatives results in
30 separation of the triphenylmethyl derivative and the biopolymer, whereas according to the present
invention the biopolymer remains bound to the trityl derivative on ionisation, thereby allowing
analysis of the biopolymer by mass spectrometry.

The invention provides methods of forming ions from covalent or ionic compounds and solid
substrates.


Derivatised Biopolymers

The invention provides a method of forming an ion of formula (I):




comprising the steps of:

- 5 (i) reacting a compound of the formula (IIa):



with a biopolymer, B_P , having at least one group capable of reacting with M to form a covalent linkage, to provide a biopolymer derivative of the formula (IIIa):



- 10 (ii) cleaving the C—X bond between X and the α -carbon atom of the derivative of formula (IIIa) to form the ion of formula (I);

where:

C \star is a carbon atom bearing a single positive charge or a single negative charge;

X is a group capable of being cleaved from the α -carbon atom to form an ion of formula (I);

- 15 M is independently a group capable of reacting with B_P to form the covalent linkage;

B_P' is independently the biopolymer residue of B_P produced on formation of the covalent linkage;

M' is independently the residue of M produced on formation of the covalent linkage;

Ar^1 is independently an aromatic group or an aromatic group substituted with one or more A;

- 20 Ar^2 is independently an aromatic group or an aromatic group substituted with one or more A;

optionally wherein (a) two or three of the groups Ar^1 and Ar^2 are linked together by one or more L^5 , where L^5 is independently a single bond or a linker atom or group; and/or (b) two or three of the groups Ar^1 and Ar^2 together form an aromatic group or an aromatic group substituted with one or more A;

- 25 A is independently a substituent;

L_M is independently a single bond or a linker atom or group;


$n = 0, 1$ or 2 and $m = 1, 2$, or 3 , provided the sum of $n+m = 3$;

p independently = 1 or more; and

q independently = 1 or more.

- 30 The invention further provides a method of forming an ion of formula (I), comprising the steps of:


- (i) reacting a compound of the formula (IIb):



X★

(IIb);

with a biopolymer, B_P, having at least one group capable of reacting with M to form a covalent linkage, to provide a biopolymer derivative of the formula (IIIb):



X★

(IIIb); and

dissociating X★ from the derivative of formula (IIIb), to form the ion of formula (I);

where:

X★ is a counter-ion to C★;

and C★, M, B_P', M', Ar¹, Ar², L_M, n, m, p and q are as defined above.

- 10 The compounds of formulae (IIa) or (IIb) may optionally be purified after step (i).

The invention also provides biopolymer derivatives of the formula (IIIa) or (IIIb), as defined above. The biopolymer derivatives of the invention have enhanced ionisability with respect to free biopolymer, B_P. Advantageously, the biopolymer derivatives may not require a matrix (*e.g.* as used in MALDI-MS) in order to elicit ionisation, although a matrix may help to enhance ionisation.

- 15 Preferably, ionisation may be obtained without requiring acid treatment, in particular by direct laser illumination.

The invention also provides ions of formula (I), as defined above. These ions are stabilised by the resonance effect of the aromatic groups Ar¹ and Ar². Electron-withdrawing groups, when C★ is an anion, or electron-donating groups, when C★ is a cation, may optionally be provided on Ar¹ and/or Ar² to assist this resonance effect. Consequently, the biopolymer derivatives of the invention readily form ions of formula (I) relative to the native biopolymer, B_P.

- 20 Ar² to assist this resonance effect. Consequently, the biopolymer derivatives of the invention readily form ions of formula (I) relative to the native biopolymer, B_P.

The ions of formula (I) are generally only ever seen on a mass spectrum with a single charge, which is advantageous since it reduces cluttering of the mass spectrum.

- 25 The invention also provides compounds of the formula (IIa) and (IIb), as defined above. As mentioned above, these compounds are useful for forming ions of formula (I). As the difference in the molecular mass of the ions of formula (I) and that of the free biopolymer can be accurately calculated, the derivatised compounds of the invention allow analysis of the biopolymer B_P, which may be otherwise difficult or impossible to analyse using known mass spectrometrical techniques.

- 30 Other advantageous features of the compounds of the invention include more uniformity of the signal intensity between different analytes (useful for quantitative studies) and similar desorption properties

between compounds with different, but close, masses, so that techniques such as isotope coded affinity tagging (ICAT) can be employed with the compounds of the invention.




The homogeneous methods of the invention are particularly appropriate for small molecules, *e.g.* amines.

5 Solid Supports



The ions of formula (I) may also be formed using a derivatised solid support.


The invention therefore provides a method of forming an ion of formula (I) comprising the steps of:

- (i) reacting a solid support of formula (IVai), (IVaii), or (IVaiii):



with a biopolymer, B_P , having at least one group capable of reacting with M to form a covalent linkage, to provide a modified solid support of the formula (Vai), (Vaii), or (Vaiii), respectively:





and either:

5 (iia) for modified solid supports of formula (Vai) cleaving the C-S_S bond between the α-carbon atom of the modified solid support of formula (Vai) and the solid support S_S to form the ion of formula (I);

(iib) for modified solid supports of formula (Vaii), either simultaneously or sequentially, cleaving the C-X bond between X and the α-carbon atom and cleaving the S_S - -Ar¹ bond between the solid support and the Ar¹ group to form the ion of formula (I); or

10 (iic) for modified solid supports of formula (Vaiii), either simultaneously or sequentially, cleaving the C-X bond between X and the α-carbon atom and cleaving the S_S - -Ar² bond between the solid support and the Ar² group to form the ion of formula (I);

where:

X, Ar¹, Ar², B_P', L_M, M, M', n, m, p and q are as defined above;

S_S is a solid support;

15 C- -S_S comprises a cleavable bond between C and S_S;



S_S - -Ar¹ comprises a cleavable bond between Ar¹ and S_S; and

S_S - -Ar² comprises a cleavable bond between Ar² and S_S.



The cleavable bond of C- -S_S, S_S - -Ar¹ or S_S - -Ar² may be a covalent, ionic, hydrogen, dipole-dipole or van der Waals bond.

20 The invention further provides a method of forming an ion of formula (I) comprising the steps of:

(i) reacting a solid support of formula (IVbii) or (IVbiii):



with a biopolymer, B_P, having at least one group capable of reacting with M to form a covalent linkage, to provide a modified solid support of the formula (Vbii) or (Vbiii), respectively:



5 and either:



(iia) for modified solid supports of formula (Vbii), either simultaneously or sequentially, dissociating X★ from the derivative of formula (Vbii) and cleaving the S_S- -Ar¹ bond between the solid support and the Ar¹ group to form an ion of formula (I); or

10 (iib) for modified solid supports of formula (Vbiii), either simultaneously or sequentially, dissociating X★ from the derivative of formula (Vbiii) and cleaving the S_S- -Ar² bond between the solid support and the Ar² group to form an ion of formula (I);



where: X★, Ar¹, Ar², B_P', L_M, M, M', n, m, p, q, S_S, C- -S_S, S_S- -Ar¹ and S_S- -Ar² are as defined above.

The invention further provides a method of forming an ion of formula (I) comprising the steps of:

15 (i) reacting a solid support of formula (IVaiv) or (IVbiv):



with a biopolymer, B_p, having at least one group capable of reacting with M to form a covalent linkage, to provide a modified solid support of the formula (Vaiv) or (Vbiv), respectively:



5 and either:

(iia) for modified solid supports of formula (Vaiv), cleaving the C-X bond between X and the α-carbon atom to form the ion of formula (I); or

(iib) for modified solid supports of formula (Vbiv), dissociating X★ from the derivative of formula (Vbiv) to form the ion of formula (I);

10 where:

X, X★, Ar¹, Ar², B_p', L_M, M, M', p, q, n, m, and S_S are as defined above;

M"-S_S comprises a bond between M" and S_S; and

M" is the same as M except that S_S is bound to a portion of M which does not form part of M'.

15 In this embodiment of the invention, the solid support is bound to a part of group M" which does not go on to form the residue M'. Thus, the derivatised biopolymer will be released from the solid support during the derivatisation step and an additional step of cleaving the biopolymer from the solid support is not required.

20 The modified solid supports of formulae (Vai), (Vaii), (Vaiii), (Vaiv), (Vbii), (Vbiii) or (Vbiv) may optionally be washed after step (i).

The invention also provides solid supports of the formulae (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) and (IVbiv), as defined above. Similarly, the invention provides modified solid supports of the formulae (Vai), (Vaii), (Vaiii), (Vaiv), (Vbii), (Vbiii), and (Vbiv), as defined above.

25 The heterogeneous methods of the invention are particularly appropriate for synthetic biopolymers, e.g. oligonucleotides, peptides and carbohydrates.

Methods of Analysis

The invention also provides a method for analysing a biopolymer, B_P, comprising the steps of:

- (i) reacting the biopolymer B_P with a compound of formula (IIa) or (IIb) or a solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv);
- 5 (ii) providing an ion of formula (I); and
- (iii) analysing the ion of formula (I) by mass spectrometry.

The biopolymer will typically have been obtained using a preparative or analytical process. For example, it may have been purified using various separation methods (*e.g.* 1-dimensional or 2-dimensional, reverse-phase or normal-phase separation, by *e.g.* chromatography or electrophoresis) and the separation may be based on any of a number of characteristics (*e.g.* isoelectric point, molecular weight, charge, hydrophobicity, *etc.*). Typical methods include 2D SDS-PAGE, 2D liquid chromatography (*e.g.* Multidimensional Protein Identification Technology, MudPIT, or 2D HPLC methods). The separation method can preferably interface directly with the mass spectrometer.

Known analytical techniques can thus be adapted or improved by the method of the invention. A particularly preferred method involves 2D-PAGE of a biopolymer, or mixture of biopolymers, selection of a spot of interest in the electrophoretogram, and then derivatisation and analysis of that spot using the techniques of the invention. The biopolymer may be proteolytically digested prior to its analysis (typically within the PAGE gel, but optionally digested after extraction from the gel) and/or may itself be the product of a proteolytic digest.

The invention also provides, in a method for analysing a biopolymer, B_P, the improvement consisting of: (i) reacting a biopolymer, B_P with a compound of formula (IIa) or (IIb) or a solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv); (ii) providing an ion of formula (I); and (iii) analysing the ion by mass spectrometry.

Typically, the analysis by mass spectrometry is carried out in a spectrometer which is suitable for MALDI-TOF spectrometry.

In the spectrometer, the ion source may be a matrix-assisted laser desorption ionisation (MALDI), an electrospray ionisation (ESI) ion source, a Fast-Atom Bombardment (FAB) ion source. Preferably, the ion source is a MALDI ion source. The MALDI ion source may be traditional MALDI source (under vacuum) or may be an atmospheric pressure MALDI (AP-MALDI) source. MALDI is a preferred ionisation method, although the use of a matrix is generally not required

In the spectrometer, the mass analyser may be a time of flight (TOF), quadrupole time of flight (Q-TOF), ion trap (IT), quadrupole ion trap (Q-IT), triple quadrupole (QQQ) Ion Trap or Time-Of-Flight Time-Of-Flight (TOF/TOF) or Fourier transform ion cyclotron resonance (FTICR) mass analyser. Preferably, the mass analyser is a TOF mass analyser.

Preferably, the mass spectrometer is a MALDI-TOF mass spectrometer.

Further Embodiments

M' bound to B_P' by a non-covalent linker

The above-mentioned embodiments of the invention may also be provided in which M' is bound to B_P' by a non-covalent bond. All the other features of the invention are the same except the groups
5 which relate to the non-covalent bond between M' and B_P'.

The non-covalent bond may be direct between M' and B_P' or may be provided by one or more binding groups present on M' and/or B_P'.

Preferred non-covalent bonds are those having an association constant (K_a) of at least 10^{14} M^{-1} , preferably about 10^{15} M^{-1} .

- 10 In preferred embodiment, one of M' and B_P' will have a binding group comprising biotin, and the other of M' and B_P' will have a binding group comprising avidin or streptavidin.

Preferably, when the compounds of the invention comprise a non-covalent bond between M' and B_P' and a cleavable bond between C and S_S, Ar¹ and S_S, or Ar² and S_S, these bonds are differentially cleavable. More preferably, the non-covalent bond between M' and B_P' is not cleaved under
15 conditions which the cleavable bond between C and S_S, Ar¹ and S_S, or Ar² and S_S, as appropriate, is cleaved.

L_M bound to Ar¹ by more than one bond

The above-mentioned embodiments of the invention may also be provided in which L_M is bound to Ar¹ by more than one covalent bond (e.g. 2 or 3 bonds) which are either single, double or triple
20 covalent bonds, or one or more multiple bonds (e.g. double or triple covalent bonds). All the other features of the invention are the same except the groups which relate to the bond or bonds between Ar¹ and L_M.


Ionisation of Compounds other than Biopolymers

In addition to biopolymers, the present invention may be used for ionising any molecule or complex
25 of molecules which requires mass spectrum analysis. Thus, the above-mentioned embodiments of the invention may also be provided in which B_P is replaced by any molecule or complex having at least one group capable of reacting with M to form a covalent linkage. All the other features of the invention are the same, except group M is group capable of reacting with the molecule to be analysed.

- 30 Examples of other molecules which may be analysed in the present invention include non-biological polymers (e.g. synthetic polyesters, polyamides and polycarbonates), petrochemicals and small molecules (e.g. alkanes, alkenes, amines, alcohols, esters and amides). Amines are particularly preferred.


Examples of complexes which may be analysed in the present invention include double- and triple-stranded RNA, DNA and/or peptide nucleic acid (PNA) complexes, enzyme/substrate complexes, multimeric proteins (*e.g.* dimers, trimers, tetramers, pentamers, *etc.*), virions, *etc.*

5 Preferably, when the compound to be ionised is not a biopolymer, all embodiments of the invention (including products of formulae (I), (IIa), (IIb), (IIIa), (IIIb), (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii), (IVbiv), (Vai), (Vaii), (Vaiii), (Vaiv), (Vbii), (Vbiii) and (Vbiv), methods of forming an ion of formula (I) and methods of analysis) involving or relating to the compound of formula (XI) are disclaimed.




10 Disclaimers


Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XI) are disclaimed




15 Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIa) are disclaimed




Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIb) are disclaimed.




Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIc) are disclaimed




- 5 Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIId) are disclaimed




Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIe) are disclaimed



Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIe) are disclaimed




5 Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIg-j) are disclaimed



Ar = p-anisyl

Formula	Base
XIg	Uridine
XIh	N ⁴ -benzoyl-cytidine
XIi	N ⁶ -benzoyl-adenosine
XIj	N ² -phenylacetyl-guanosine

10 Preferably, all embodiments of the invention (including products of formulae (I) and (IIa)) involving or relating to the compound of formula (XIk-n) are disclaimed




Ar = p-anisyl

Formula	Base
XIk	Uridine
XII	N ⁴ -benzoyl-cytidine
XIm	N ⁶ -benzoyl-adenosine
XIn	N ² -phenylacetyl-guanosine

Preferred Embodiments

5 Definition of C ★

Preferably, C ★ bears a single positive charge such that ions of the invention are cations and the ion of formula (I) has the following structure:



and the compounds of formulae (IIb), (IIIb), (IVbii), (IVbiii), (IVbiv), (Vbii), (Vbiii) and (Vbiv)

10 have the structures disclosed in table 1.

n, m, p and q


For the purposes of compounds of the invention having $n-1$ groups Ar^2 , n may not be less than 1.

Preferably $n = 2$ and $m = 1$.

Preferably $p = 1, 2$ or 3 . Preferably $p = 1$.

15 Preferably $q = 1, 2$ or 3 . Preferably $q = 1$.

Preferably $n = 2, m = 1, p = 1$ and $q = 1$. The ion of formula (I) thus has the structure:



and the compounds of formulae (IIa), (IIb), (IIIa), (IIIb), (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii), (IVbiv), (Vai), (Vaii), (Vaiii), (Vaiv), (Vbii), (Vbiii) and (Vbiv) have the structures

20 disclosed in table 2.

Biopolymers


The term 'biopolymer' includes polymers found in biological samples, including polypeptides, polysaccharides, and polynucleotides (e.g. DNA or RNA). Polypeptides may be simple copolymers of amino acids, or they may include post-translational modifications e.g. glycosylation, lipidation, phosphorylation, etc. Polynucleotides may be single-stranded (in whole or in part), double-stranded (in whole or in part), DNA/RNA hybrids, etc. RNA may be mRNA, rRNA or tRNA.

Advantageous biopolymers are those which do not readily form a molecular ion in known MALDI-TOF MS techniques, especially those which do not form a molecular ion on illumination of laser light at 340 nm.

Biopolymers for use in the invention comprise two or more monomers, which may be the same or different as each other. Preferred biopolymers comprise at least *pp* monomers, where *pp* is 5 or more (e.g. 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250). More preferred biopolymers comprise *ppp* or fewer monomers where *ppp* is 300 or less (e.g. 200, 100, 50).

Biopolymers may have a molecular mass of at least *qq* kDa, where *qq* = 0.5 or more (e.g. 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, etc.). Preferred biopolymers are those having a molecular mass within the range of detection of a mass spectrometer. More preferred biopolymers have a molecular mass of *qqq* kDa or less, where *qqq* is 30 or less (e.g. 20, 10, 5).

Preferably, the mass, *m*(IX), of the fragment (IX)



of the cation of formula (I) is significantly less than the mass, *m*(B_P⁺), of the biopolymer residue B_P⁺. For example the ratio *m*(B_P⁺) / *m*(IX) is preferably more than *nn*, where *nn* is at least 2 (e.g. 3, 4, 5, 10, 100, 1000, etc.).

The invention is suitable for use with purified biopolymers or mixtures of biopolymers. For example, a pure recombinant protein could be derivatised and analysed by MS, or biopolymers within a cellular lysate or extract could be derivatives and then analysed.

Preferred biopolymers are polypeptides. Particularly preferred biopolymers are polypeptides formed after proteolytic digestion of a protein.

Biopolymers bound to solid supports

In preferred embodiments of the invention the biopolymer is bound to a solid support such that it is cleavable from the solid support at least once it has been derivatised by a compound of the invention. B_P is thus derivatised *in situ* while bound to the support, and is then released. As the biopolymer is bound to the solid support, this aspect of the invention is particularly relevant to methods involving compounds of formulae (IIa) and (IIb).

The biopolymer may be bound to the solid support by a covalent, ionic, hydrogen, dipole-dipole or van der Waals bond (also known as a dispersion bond or a London forces bond). The covalent, ionic, hydrogen, dipole-dipole or van der Waals bond may be direct between the biopolymer and the solid support or may be provided by one or more binding groups present on the biopolymer and/or solid support. Preferred groups are non-covalent groups.

Examples of groups which can form these types of bond, and methods for cleaving these types of bond, are set out below in connection with C--S_S bonds, *etc.*

In a particularly preferred embodiment, the solid support is provided with $-(NMe_3)^+$ binding groups and the biopolymer has a net negative charge, or *vice versa* (*i.e.* the $-(NMe_3)^+$ is on the biopolymer).

10 In other preferred embodiments, the solid support is provided with anions such as carboxylate, phosphate or sulphate, or anions formed from acid groups, and the biopolymer (*e.g.* a histone) has a net positive charge, or *vice versa*.

Reactivity with group M


The biopolymers have at least one reactive group capable of reacting with M to form a covalent linkage. Such groups typically include naturally occurring groups and groups formed synthetically on the biopolymer.

Naturally occurring groups include lipid groups of lipoproteins (*e.g.* myristoyl, glycosylphosphatidylinositol, ethanolamine phosphoglycerol, palmitate, stearate, S- or N- or O-acyl groups, lipoic acid, isoprenyl, geranylgeranyl, farnesyl, *etc.*), amide, carbohydrate groups of N- and O- glycoproteins, amine groups (*e.g.* on lysine residues or at the N-terminus of a protein), hydroxyl (*e.g.* in β -hydroxyaspartate, β -hydroxyasparagine, 5-hydroxylysine, $\frac{3}{4}$ -hydroxyproline), thiol, sulfhydryl, phosphoryl, sulfate, methyl, acetyl, formyl (*e.g.* on N-terminal methionines from prokaryotes), phenyl, indolyl, guanidyl, hydroxyl, phosphate, methylthio, ADP-ribosyl *etc.*

The reactive group is bound to the biopolymer by one or more covalent bonds (*e.g.* 2 or 3 bonds), which are either single, double or triple covalent bonds (preferably single bonds). Preferably, the reactive group is bound to the biopolymer by one single bond.

Groups which may be formed naturally or synthetically on the biopolymer and which are bound to the biopolymer by one bond include: $-NR_2$ *e.g.* $-NHR$, especially $-NH_2$; $-SR$ *e.g.* $-SH$; $-OR$ *e.g.* $-OH$; $-B(R)Y$; $-BY_2$; $-C(R)_2Y$; $-C(R)Y_2$; $-CY_3$; $-C(=Z)Y$ *e.g.* $-C(=O)Y$; $-Z-C(=Z)Y$; $-C(=Z)R$ *e.g.* $-C(=Z)H$, especially $-C(=O)H$; $-C(R)(OH)OR$; $-C(R)(OR)_2$; $-S(=O)Y$; $-Z-S(=O)Y$; $-S(=O)_2Y$; $-Z-S(=O)_2Y$; $-S(=O)_3Y$; $-Z-S(=O)_3Y$; $-P(=Z)(ZR)Y$ *e.g.* $-P(=O)(OH)Y$; $-P(=Z)Y_2$; $-Z-P(=Z)(ZR)Y$; $-Z-P(=Z)Y_2$; $-P(=Z)(R)Y$ *e.g.* $-P(=O)(H)Y$; $-Z-P(=Z)(R)Y$; or $-N=C(=Z)$ *e.g.* $-N=C(=O)$.

Other groups which may be formed naturally or synthetically on the biopolymer and which are bound to the biopolymer by one bond are: $-P(ZR)Y$ *e.g.* $-P(OH)Y$; $-PY_2$; $-Z-P(ZR)Y$; $-Z-PY_2$; $-P(R)Y$ *e.g.* $-P(H)Y$; $-Z-P(R)Y$. A particularly preferred group is $-Z-P(ZR)Y$, especially a phosphoramidite group:



Another example of a group which may be formed naturally or synthetically on the biopolymer and which is bound to the biopolymer by one bond is $-Y$. In particular, when the reactive group is halo (especially iodo), the reactive group may be bound to an aliphatic or aromatic carbon.


- 5 Groups which may be formed synthetically on the biopolymer and which are bound to the biopolymer by two bonds include $-N(R)-$ *e.g.* $-NH-$; $-S-$; $-O-$; $-B(Y)-$; $-C(R)(Y)-$; $-CY_2-$; $-C(=O)-$; $-C(OH)(OR)-$; $-C(OR)_2-$.

Groups which may be formed synthetically on the biopolymer and which are bound to the

biopolymer by three bonds include $\text{---}\overset{\text{C}(Y)}{\underset{|}{\text{C}}}\text{---}$.



- 10 Preferred groups include nucleophilic groups, either natural or synthetic, *e.g.*: $-NR_2$ *e.g.* $-NHR$, especially $-NH_2$; $-SR$ *e.g.* $-SH$; $-OR$ *e.g.* $-OH$; $-N(R)-$ *e.g.* $-NH-$; $-S-$; and $-O-$. The groups $-NH_2$, $-SH$ and $-OH$ are particularly preferred.


Another preferred reactive group is maleimidyl:







- 15 Y is independently a leaving group, including groups capable of leaving in an SN_2 substitution reaction or being eliminated in an addition-elimination reaction with the reactive group of the biopolymer B_p .

- Preferred examples of Y include halogen (preferably iodo), C_{1-8} hydrocarbyloxy (*e.g.* C_{1-8} alkoxy), C_{1-8} hydrocarbyloxy substituted with one or more A , C_{1-8} heterohydrocarbyloxy, C_{1-8} heterohydrocarbyloxy substituted with one or more A , mesyl, tosyl, pentafluorophenyl, $-O$ -succinimidyl (formula VII) or a sulfo sodium salt thereof (sulfoNHS – formula VIIa), $-S$ -succinimidyl, or phenyloxy substituted with one or more A *e.g.* p -nitrophenyloxy (formula VIII) or pentafluorophenoxy (formula VIIa).





Thus, preferred reactive group on the biopolymer are:



Other preferred examples of Y include -ZR. Particularly preferred examples of Y are -ZH (*e.g.* -OH or -NH₂) and -Z-C₁₋₈alkyl groups such as -NH-C₁₋₈alkyl groups (*e.g.* -NHMe) and -O-C₁₋₈alkyl groups (*e.g.* -O-t-butyl). Thus, preferred reactive groups are -C(O)-NH-C₁₋₈alkyl and -C(O)-O-C₁₋₈alkyl (*e.g.* -C(O)-O-t-butyl).

Other preferred examples of Y include -Z-ZR. Particularly preferred examples include -NR-NR₂, especially -NH-NH₂, and -ONR₂, especially -O-NH₂.

Z is independently O, S or N(R). Preferred (=Z) is (=O).

R is independently H, C₁₋₈hydrocarbyl (*e.g.* C₁₋₈alkyl) or C₁₋₈hydrocarbyl substituted with one or more A.


R is preferably H.

Other preferred reactive groups include -C(=O)Y, especially -C(=O)-O-succinimidyl and -C(=O)-O-(p-nitrophenyl).

In a further embodiment, the reactive group may be $-\text{Si}(\text{R})_2\text{-Y}$, with Y being halo (e.g. chloro) being especially preferred. Preferred groups R in this embodiment are C_{1-8} alkyl, especially methyl. A particularly preferred reactive group in this embodiment is $-\text{Si}(\text{Me})_2\text{Cl}$.

Other groups which may be formed naturally or synthetically on the biopolymer include groups capable of reacting in a cycloaddition reaction, especially a Diels-Alder reaction.

In the case of Diels-Alder reactions, the reactive group on the biopolymer is either a diene or a dienophile. Preferred diene groups are




and multivalent derivatives formally formed by removal of one or more hydrogen atoms, where A^1 is $-\text{R}^1$ or $-\text{Z}^1\text{R}^1$, where R^1 and Z^1 are defined below.

Preferred dienophile groups are $-\text{CR}^1=\text{CR}^1_2$, $-\text{CR}^1=\text{C}(\text{R}^1)\text{A}^2$, $-\text{CA}^2=\text{CR}^1_2$, $-\text{CA}^2=\text{C}(\text{R}^1)\text{A}^2$ or $-\text{CA}^2=\text{CA}^2_2$, and multivalent derivatives formally formed by removal of one or more hydrogen atoms, where R^1 is defined below and A^2 is independently halogen, trihalomethyl, $-\text{NO}_2$, $-\text{CN}$, $-\text{N}^+(\text{R}^1)_2\text{O}^-$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^1$, $-\text{SO}_3\text{H}$, $-\text{SOR}^1$, $-\text{SO}_2\text{R}^1$, $-\text{SO}_3\text{R}^1$, $-\text{OC}(=\text{O})\text{OR}^1$, $-\text{C}(=\text{O})\text{H}$, $-\text{C}(=\text{O})\text{R}^1$, $-\text{OC}(=\text{O})\text{R}^1$, $-\text{OC}(=\text{O})\text{NR}^1_2$, $-\text{N}(\text{R}^1)\text{C}(=\text{O})\text{R}^1$, $-\text{C}(=\text{S})\text{NR}^1_2$, $-\text{NR}^1\text{C}(=\text{S})\text{R}^1$, $-\text{SO}_2\text{NR}^1_2$, $-\text{NR}^1\text{SO}_2\text{R}^1$, $-\text{N}(\text{R}^1)\text{C}(=\text{S})\text{NR}^1_2$, or $-\text{N}(\text{R}^1)\text{SO}_2\text{NR}^1_2$, where R^1 is defined below. A particularly preferred dienophile group is maleimidyl.

Group M

The group M is capable of reacting with the reactive group of the biopolymer, B_P , to form a covalent linkage. [Group 'M' is shown as 'AFG' in the drawings].


The group M is bound to L_M by one or more covalent bonds (e.g. 2 or 3 bonds, especially 2 such



as), which are either single, double or triple covalent bonds (preferably single bonds).


Preferably, M is bound to L_M by one single bond.

Alternatively, or in addition, M is bound by more than one L_M , such L_M either being attached to the same or different Ar^1 or Ar^2 . In a preferred embodiment M is bound by more than one L_M from different Ar^1 or Ar^2 , e.g.:



Examples of group M bound to L_M by one bond include $-NR_2$ *e.g.* $-NHR$, especially $-NH_2$; $-SR$ *e.g.* $-SH$; $-OR$ *e.g.* $-OH$; $-B(R)Y$; $-BY_2$; $-C(R)_2Y$; $-C(R)Y_2$; $-CY_3$; $-C(=Z)Y$ *e.g.* $-C(=O)Y$; $-Z-C(=Z)Y$; $-C(=Z)R$ *e.g.* $-C(=Z)H$, especially $-C(=O)H$; $-C(R)(OH)OR$; $-C(R)(OR)_2$; $-S(=O)Y$; $-Z-S(=O)Y$; $-S(=O)_2Y$; $-Z-S(=O)_2Y$; $-S(=O)_3Y$; $-Z-S(=O)_3Y$; $-P(=Z)(ZR)Y$ *e.g.* $-P(=O)(OH)Y$; $-P(=Z)Y_2$; $-Z-P(=Z)(ZR)Y$; $-Z-P(=Z)Y_2$; $-P(=Z)(R)Y$ *e.g.* $-P(=O)(H)Y$; $-Z-P(=Z)(R)Y$; or $-N=C(=Z)$ *e.g.* $-N=C(=O)$.

Other examples of group M bound to L_M by one bond are $-P(ZR)Y$ *e.g.* $-P(OH)Y$; $-PY_2$; $-Z-P(ZR)Y$; $-Z-PY_2$; $-P(R)Y$ *e.g.* $-P(H)Y$; $-Z-P(R)Y$. A particularly preferred group M is $-Z-P(ZR)Y$, especially a phosphoramidite group:



Another example of group M bound to L_M by one bond is $-Y$. In particular, when group M is halo (especially iodo), M may be bound to an aliphatic or aromatic carbon. When M is halo (*e.g.* iodo) and is bound to an aromatic carbon, L_M may, for example, be a single bond.

Examples of group M bound to L_M by two bonds include $-N(R)-$ *e.g.* $-NH-$; $-S-$; $-O-$; $-B(Y)-$;

$-C(R)(Y)-$; $-CY_2-$; $-C(=O)-$; $-C(OH)(OR)-$; $-C(OR)_2-$.


Examples of group M bound to L_M by three bonds include $\text{---}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}(Y)\text{---}$.

Preferred groups M include electrophilic groups, especially those susceptible to SN_2 substitution reactions, addition-elimination reactions and addition reactions, *e.g.* $-B(R)Y$; $-BY_2$; $-C(R)_2Y$; $-C(R)Y_2$; $-CY_3$; $-C(=Z)Y$ *e.g.* $-C(=O)Y$; $-Z-C(=Z)Y$; $-C(=Z)R$ *e.g.* $-C(=Z)H$, especially $-C(=O)H$; $-C(R)(OH)OR$; $-C(R)(OR)_2$; $-S(=O)Y$; $-Z-S(=O)Y$; $-S(=O)_2Y$; $-Z-S(=O)_2Y$; $-S(=O)_3Y$; $-Z-S(=O)_3Y$; $-P(=Z)(ZR)Y$ *e.g.* $-P(=O)(OH)Y$; $-P(=Z)Y_2$; $-Z-P(=Z)(ZR)Y$; $-Z-P(=Z)Y_2$; $-P(=Z)(R)Y$ *e.g.* $-P(=O)(R)Y$; $-Z-P(=Z)(H)Y$; $-N=C(=Z)$ *e.g.* $-N=C(=O)$; $-B(Y)-$; $-C(R)(Y)-$; $-CY_2-$; $-C(=O)-$;

$-C(OH)(OR)-$; $-C(OR)_2-$; or $\text{---}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}(Y)\text{---}$.

Still further preferred examples of group M are orthoesters, *e.g.* $-C(OR)_3$. In a preferred embodiment,





the R groups are linked together to form a hydrocarbyl group, *e.g.* a C_{1-3} alkyl group. A preferred example of group M in this embodiment is:







Another preferred group M is maleimido.

Y, Z and R are defined as above. Preferred Y groups when present on M are those capable of leaving in an SN_2 substitution reaction or being eliminated in an addition-elimination reaction with the reactive group of the biopolymer B_p .

- Preferred examples of Y include halogen (preferably iodo), C_{1-8} hydrocarbyloxy (e.g. C_{1-8} alkoxy), C_{1-8} hydrocarbyloxy substituted with one or more A, C_{1-8} heterohydrocarbyloxy, C_{1-8} heterohydrocarbyloxy substituted with one or more A, mesyl, tosyl, pentafluorophenyl, -O-succinimidyl (formula VII) or a sulfo sodium salt thereof (sulfoNHS – formula VIIa), -S-succinimidyl, or phenyloxy substituted with one or more A e.g. p-nitrophenyloxy (formula VIII) or pentafluorophenoxy (formula VIIIa).



Thus, preferred groups M are:




- Other preferred examples of Y include -ZR. Particularly preferred examples of Y are -ZH (e.g. -OH or -NH₂) and -Z- C_{1-8} alkyl groups such as -NH- C_{1-8} alkyl groups (e.g. -NHMe) and -O- C_{1-8} alkyl groups (e.g. -O-t-butyl). Thus, preferred groups M are -C(O)-NH- C_{1-8} alkyl (e.g. -C(O)NHMe) and -C(O)-O- C_{1-8} alkyl (e.g. -C(O)-O-t-butyl).

Other preferred examples of Y include -Z-ZR. Particularly preferred examples include -NR-NR₂, especially -NH-NH₂, and -ONR₂, especially -O-NH₂.

- Particularly preferred groups M include -C(=O)Y, especially -C(=O)-O-succinimidyl and -C(=O)-O-(p-nitrophenyl).


In a further embodiment, M may be -Si(R)₂-Y, with Y being halo (e.g. chloro) being especially preferred. Preferred groups R in this embodiment are C_{1-8} alkyl, especially methyl. A particularly preferred group M in this embodiment is -Si(Me)₂Cl.

- In a further embodiment, M may be -C(Ar²)₂X. Preferred groups Ar² and X are set out below. In this embodiment it is preferred that L_M is a bond. A particularly preferred group M in this embodiment is:



Other groups M include groups capable of reacting in a cycloaddition reaction, especially a Diels-Alder reaction.

In the case of Diels-Alder reactions, the reactive group on the biopolymer is either a diene or a
5 dienophile. Preferred diene groups are



and multivalent derivatives formally formed by removal of one or more hydrogen atoms, where A¹ is -R¹ or -Z¹R¹, where R¹ and Z¹ are defined below.

Preferred dienophile groups are -CR¹=CR¹², -CR¹=C(R¹)A², -CA²=CR¹², -CA²=C(R¹)A² or
10 -CA²=CA²², and multivalent derivatives formally formed by removal of one or more hydrogen atoms, where R¹ is defined below and A² is independently halogen, trihalomethyl, -NO₂, -CN, -N⁺(R¹)₂O⁻, -CO₂H, -CO₂R¹, -SO₃H, -SOR¹, -SO₂R¹, -SO₃R¹, -OC(=O)OR¹, -C(=O)H, -C(=O)R¹, -OC(=O)R¹, , -OC(=O)NR¹², -N(R¹)C(=O)R¹, -C(=S)NR¹², -NR¹C(=S)R¹, -SO₂NR¹², -NR¹SO₂R¹, -N(R¹)C(=S)NR¹², or -N(R¹)SO₂NR¹², where R¹ is defined below. A particularly preferred dienophile
15 group is maleimidyl.

Preferred examples of group M are shown in figures 11A and 11B.

Matching B_p and M

The reactive group on the biopolymer [shown as 'F' in the drawings] and the group M [shown as 'AFG' in the drawings] must be dependently selected in order to form the covalent linkage. For
20 example, where the biopolymer includes the groups -NH₂, -OH or -SH, M will typically be -B(R)Y; -BY₂; -C(R)₂Y; -C(R)Y₂; -CY₃; -C(=Z)Y e.g. -C(=O)Y; -Z-C(=Z)Y; -C(=Z)R e.g. -C(=Z)H, especially -C(=O)H; -C(R)(OH)OR; -C(R)(OR)₂; -S(=O)Y; -Z-S(=O)Y; -S(=O)₂Y; -Z-S(=O)₂Y; -S(=O)₃Y; -Z-S(=O)₃Y; -P(=Z)(ZR)Y e.g. -P(=O)(OH)Y; -P(=Z)Y₂; -Z-P(=Z)(ZR)Y; -Z-P(=Z)Y₂;



$-P(=Z)(R)Y$ e.g. $-P(=O)(H)Y$; $-Z-P(=Z)(R)Y$; $-N=C(=Z)$ e.g. $-N=C(=O)$; $-B(Y)-$; $-C(R)(Y)-$; $-CY_2-$;

$-C(=O)-$; $-C(OH)(OR)-$; $-C(OR)_2-$; or $\begin{array}{c} | \\ -C(Y)- \end{array}$.

In a preferred embodiment, one of the reactive group on the biopolymer and group M is a maleimidyl and the other will be a $-SH$ group.

- 5 Alternatively, when the covalent linkage is to be formed by a Diels Alder reaction, one of the reactive group on the biopolymer and group M will typically be a diene and the other will be a dienophile.

Preferred covalent linkages are those produced through the reaction of the following groups:

M	Group on B _P	Obtained Linkage M'-B _P '
$-C(=O)-O$ -succinimidyl [<i>i.e.</i> carboxy-NHS]	$-NH_2$	$-CO-NH-$
$-C(=O)-O$ -(p-nitrophenyl)	$-NH_2$	$-CO-NH-$
$-C(=O)-O$ -pentafluorophenyl	$-NH_2$	$-CO-NH-$
Biotin	avidin / streptavidin	biotin-(strept)avidin
	$-SH$	
$-N=C=S$ (isothiocyanate)	$-NH_2$	$-NH-CS-NH-$

- 10 The covalent residue M'-B_P' is the reaction product of M and B_P. B_P' will generally be the same as B_P except that instead of the reactive group, B_P' will have a residue of the reactive group covalently bound to the residue M'. Depending on the choice of the reactive group and the choice of M, M' and the residue of the reactive group will typically form linkages, in the orientation L_M-M'-B_P', including
- 15 $-C(R)_2Z-$, $-ZC(R)_2-$, $-C(=Z)Z-$, $-ZC(=Z)-$, $-ZC(=Z)Z-$, $-C(OH)(R)Z-$, $-ZC(OH)(R)-$, $-C(R)(OR)Z-$, $-ZC(R)(OR)-$, $-C(R)(OR)Z-$, $-ZC(R)(OR)-$, $-S(=O)Z-$, $-ZS(=O)-$, $-ZS(=O)Z-$, $-S(=O)_2Z-$, $-ZS(=O)_2-$, $-ZS(=O)_2Z-$, $-S(=O)_3Z-$, $-ZS(=O)_3-$, $-ZS(=O)_3Z-$, $-P(=Z)(ZR)Z-$, $-ZP(=Z)(ZR)-$, $-ZP(=Z)(ZR)Z-$, $-P(=Z)(R)Z-$, $-ZP(=Z)(R)-$, $-ZP(=Z)(R)Z-$, $-NH-C(=Z)-Z-$, where Z and R are as defined above.

Group M''

- M'' is the same as M except that the group S_S is bound to a portion of M which does not form part of
- 20 M'. Thus, M'' is a residue of M formable by the conjugation of M and S_S. However, M'' need not necessarily be formed by the conjugation of M and S_S.


M''-S_S comprises a covalent, ionic, dipole-dipole, hydrogen, or van der Waals bond. The covalent, ionic, hydrogen, dipole-dipole or van der Waals bond may be direct between M'' and S_S or may be provided by one or more binding groups present on M'' and/or S_S.

Examples of groups which can form these types of bond, and methods for cleaving these types of bond, are set out below in connection with C--S_S bonds, *etc.*

This embodiment of the invention is advantageous, since the derivatisation of the biopolymer will also release the derivatised biopolymer from the solid support. Thus, an additional step of cleaving the biopolymer from the solid support is not required.

Preferred groups M'' are groups M having a leaving group, wherein the group S_S is bound to the leaving group, *e.g.* groups M mentioned above having a leaving group Y, wherein the group S_S is bound to the leaving group Y.

A particularly preferred group M'' is:



L_M

Where the group L_M is a linker atom or group, it has a sufficient number of linking covalent bonds to link L_M to the group Ar^1 by a single covalent bond (or more, as appropriate) and to link L_M to the p instances of M (or M', as appropriate) groups (which may be attached to L_M by one or more bonds).

The group L_M may be directly bound to the aromatic part of Ar^1 , bound to one or more of the substituents A of Ar^1 , or both. Preferably, L_M is bound directly to the aromatic part of Ar^1 .

In an alternative embodiment, L_M may be bound to L_5 .


When L_M is a linker atom, preferred linker atoms are O or S, particularly O.

When L_M is a linker group, preferred linker groups, in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, are $-E^M-$, $-(D^M)_t-$, $-(E^M-D^M)_t-$, $-(D^M-E^M)_t-$, $-E^M-(D^M-E^M)_t-$ or $-D^M-(E^M-D^M)_t-$, where a sufficient number of linking covalent bonds, in addition to the covalent bonds at the chain termini shown, are provided on groups E^M and D^M for linking the p instances of M (or M') groups.


D^M is independently C_{1-8} hydrocarbylene or C_{1-8} hydrocarbylene substituted with one or more A. Preferred D^M are C_{1-8} alkylene, C_{1-8} alkenylene and C_{1-8} alkynylene, especially C_{1-8} alkylene and C_{1-8} alkynylene, each optionally substituted with one or more A (preferably unsubstituted). A preferred substituent A is 2H . Preferred L_M in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, are: $-CH_2CH_2-$; $-C\equiv C-CH_2CH_2CH_2-$; $-(CH_2)_5-$; $-CD_2CD_2CH_2CH_2CH_2-$; $-C\equiv C-CH_2-$ and $-CH_2CH_2CH_2-$.

- E^M , in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, is independently $-Z^M-$, $-C(=Z^M)-$, $-Z^MC(=Z^M)-$, $-C(=Z^M)Z^M-$, $-Z^MC(=Z^M)Z^M-$, $-S(=O)-$, $-Z^MS(=O)-$, $-S(=O)Z^M-$, $-Z^MS(=O)Z^M-$, $-S(=O)_2-$, $-Z^MS(=O)_2-$, $-S(=O)_2Z^M-$, $-Z^MS(=O)_2Z^M-$, where Z^M is independently O, S or $N(R^M)$ and where R^M is independently H, C_{1-8} hydrocarbonyl (e.g. C_{1-8} alkyl) or C_{1-8} hydrocarbonyl substituted with one or more A. Preferably E^M is, in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, $-O-$, $-S-$, $-C(=O)-$, $-C(=O)O-$, $-C(=S)-$, $-C(=S)O-$, $-OC(=S)-$, $-C(=O)S-$, $-SC(=O)-$, $-S(O)-$, $-S(O)_2-$, $-NR^M-$, $-C(=O)N(R^M)-$, $-C(=S)N(R^M)-$, $-N(R^M)C(=O)-$, $-N(R^M)C(=S)-$, $-S(=O)N(R^M)-$, $-N(R^M)S(=O)-$, $-S(=O)_2N(R^M)-$, $-N(R^M)S(=O)_2-$, $-OC(=O)O-$, $-SC(=O)O-$, $-OC(=O)S-$, $-N(R^M)C(=O)O-$, $-OC(=O)N(R^M)-$, $-N(R^M)C(=O)N(R^M)-$, $-N(R^M)C(=S)N(R^M)-$, $-N(R^M)S(=O)N(R^M)-$ or $-N(R^M)S(=O)_2N(R^M)-$.


- Alternative groups E^M to those defined above, in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, are $-Z^M-Si(R^M)_2-Z^M-$, $-Si(R^M)_2-Z^M-$ and $-Z^M-Si(R^M)_2-$. The group $-Si(R^M)_2-Z^M-$ is particularly preferred. Z^M is preferably O. R^M is preferably C_{1-8} alkyl, preferably methyl. These groups E^M are particularly preferred in the groups $-(E^M-D^M)_t-$, especially when $t=1$ and D^M is C_{1-8} alkylene. The following group is especially preferred:



In addition to the above definition of D^M , D^M may also be C_{1-8} heterohydrocarbonylene or C_{1-8} heterohydrocarbonylene substituted with one or more A. In this embodiment,



- C_{1-8} cycloheteroalkylene groups are particularly preferred, e.g.: groups $-D^M-E^M-D^M-$ are, in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, $-C_{1-8}$ alkylene- $C(O)-C_{1-8}$ cycloheteroalkylene (preferably where the hetero atom is N and is bound to the carboxy), especially:



- $t = 1$ or more, e.g. from 1 to 50, 1 to 40, 1 to 30, 1 to 20 or 1 to 10. Preferably $t = 1, 2, 3, 4, 5, 6, 7, 8, 9$, or 10.

Preferably, L_M links one group M (or M') to Ar^1 , M (or M') is linked to L_M by a single covalent bond and therefore no additional bonds are required (e.g. $L_M\{M\}_1$ may be $-E^M-\{M\}$, $-(D^M)_t-\{M\}$, $-(E^M-D^M)_t-\{M\}$, $-(D^M-E^M)_t-\{M\}$, $-E^M-(D^M-E^M)_t-\{M\}$ or $-D^M-(E^M-D^M)_t-\{M\}$).


- Where L_M includes a group which also falls within the definition of group M, the group M is preferably more reactive than the group included in L_M .

L_M is preferably $-(D^M)_t-$, $-(E^M-D^M)_t-$, or $-D^M-(E^M-D^M)_t-$.

When group L_M is $-(D^M)_t-$, t is preferably 1. D^M is preferably C_{1-8} alkylene, preferably methylene or ethylene.

When group L_M is $-(E^M-D^M)_t-$, or $-D^M-(E^M-D^M)_t-$, E^M is preferably (in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate), $-C(=O)N(R^M)-$ (e.g. $-C(=O)NH-$) or O (preferably O), and D^M is preferably C_{1-8} alkylene, preferably ethylene, propylene, butylene or pentylene (preferably ethylene or propylene). t is preferably 1. Especially preferred L_M are, in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, $-O-CH_2CH_2CH_2-$ and $-O-CH_2CH_2CH_2CH_2CH_2-$.

Another preferred group $-D^M-(E^M-D^M)_t-$ is where D^M is C_{1-8} alkylene and t is 1. Preferred E^M in this group, in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate, are $-Z^MC(=Z^M)-$ (especially $-N(R^M)C(=O)-$, e.g. $-N(Me)C(=O)-$) and $-C(=Z^M)Z^M-$ (especially $-C(=O)O-$). Particularly preferred L_M groups are:



The group $-(E^M-D^M)_t-$ is preferred, a particularly preferred example of which is (in the orientation $Ar^1-(L_M\{M\}_p)_q$ or $Ar^1-(L_M\{M'\}_p)_q$, as appropriate) $-C(=O)NH-CH_2CH_2CH_2-O-CH_2CH_2-O-CH_2CH_2-O-CH_2CH_2CH_2-$.

In an alternative embodiment it is preferred that L_M is a single covalent bond.

When Ar^2 is phenyl, L_M is preferably provided in a position ortho or para to C^\star . When Ar^2 is other than phenyl, L_M is preferably attached to an atom which bears the charge in at least one of the resonance structures of the ions of formula (I).

Where C^\star is a cation, L_M is preferably an electron-donating group. Where C^\star is an anion, L_M is preferably an electron-withdrawing group.

Preferred examples of L_M are shown in figure 10A and 10B.

C--S_S, S_S--Ar¹ and S_S--Ar² Bonds

- C--S_S, S_S--Ar¹ and S_S--Ar² comprise a cleavable covalent, ionic, hydrogen, dipole-dipole or van der Waals bond (also known as a dispersion bond or a London forces bond). The covalent, ionic, hydrogen, dipole-dipole or van der Waals bond may be direct between C and S_S, Ar¹ and S_S, or Ar² and S_S, or may be provided by one or more binding groups present on C and/or S_S, Ar¹ and/or S_S, or Ar² and/or S_S, respectively.

Covalent Bonding

Where the bond is covalent, the bond may be direct (e.g. C-S_S, Ar¹-S_S or Ar²-S_S, respectively) or may be provided by a linker atom or group L⁴ (e.g. C-L⁴-S_S, Ar¹-L⁴-S_S or Ar²-L⁴-S_S, respectively).

- 10 When L⁴ is a linker group, preferred linker groups are -E⁴-, -(D⁴)_{t''}-, -(E⁴-D⁴)_{t''}-, -(D⁴-E⁴)_{t''}-, -E⁴-(D⁴-E⁴)_{t''}- or -D⁴-(E⁴-D⁴)_{t''}-.

D⁴ is independently C₁₋₈hydrocarbylene or C₁₋₈hydrocarbylene substituted with one or more A.

- E⁴ is, in the orientation C-L⁴-S_S, independently -Z⁴-, -C(=Z⁴)-, -Z⁴C(=Z⁴)-, -C(=Z⁴)Z⁴-, -Z⁴C(=Z⁴)Z⁴-, -S(=O)-, -Z⁴S(=O)-, -S(=O)Z⁴-, -Z⁴S(=O)Z⁴-, -S(=O)₂-, -Z⁴S(=O)₂-, -S(=O)₂Z⁴-, -Z⁴S(=O)₂Z⁴-, where
- 15 Z⁴ is independently O, S or N(R⁴), and where R⁴ is independently H, C₁₋₈hydrocarbyl (e.g. C₁₋₈alkyl) or C₁₋₈hydrocarbyl substituted with one or more A. Preferably E⁴ is, in the orientation C-L⁴-S_S, -O-, -S-, -C(=O)-, -C(=O)O-, -C(=S)-, -C(=S)O-, -OC(=S)-, -C(=O)S-, -SC(=O)-, -S(O)-, -S(O)₂-, -N(R⁴)-, -C(=O)N(R⁴)-, -C(=S)N(R⁴)-, -N(R⁴)C(=O)-, -N(R⁴)C(=S)-, -S(=O)N(R⁴)-, -N(R⁴)S(=O)-, -S(=O)₂N(R⁴)-, -N(R⁴)S(=O)₂-, -OC(=O)O-, -SC(=O)O-, -OC(=O)S-, -N(R⁴)C(=O)O-,
- 20 -OC(=O)N(R⁴)-, -N(R⁴)C(=O)N(R⁴)-, -N(R⁴)C(=S)N(R⁴)-, -N(R⁴)S(=O)N(R⁴)- or -N(R⁴)S(=O)₂N(R⁴)-.

t'' = 1 or more, e.g. from 1 to 50, 1 to 40, 1 to 30, 1 to 20 or 1 to 10. Preferably t'' = 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

- Where L⁴ includes a group which also falls within the definition of group M, the group M is
- 25 preferably more reactive than the group included in L⁵.

L⁴ is preferably a linker atom, preferably O or S, particularly O.

When the solid support S_S is gold, L⁴ is preferably covalently attached to the S_S by a sulphide or disulphide group.

Ionic Bonding

- 30 Where the bond is ionic, the bond is typically direct (e.g. C★ S_S★, where S_S★ is a solid support counterion to C★).

Alternatively, it may be provided by binding groups, e.g. chelating ligands, present on C or S_S, Ar¹ or S_S, or Ar² or S_S, respectively. In the case of C--S_S bonds, the chelating ligand is typically only present on S_S and chelates with C★.

Suitable chelating ligands which can bind anions include polyamines and cryptands.

Suitable chelating ligands which can bind cations include polyacidic compounds (e.g. EDTA) and crown ethers.

Hydrogen Bonding

- 5 Where the bond is a hydrogen bond, the bond is usually provided by binding groups present on C or S_s , Ar^1 or S_s , or Ar^2 or S_s , respectively.

Typically, in order to form the hydrogen bond, one of C or S_s , Ar^1 or S_s , or Ar^2 or S_s , as appropriate, will have a binding group bearing one or more hydroxy, amino or thio hydrogen atoms, and the other of C or S_s , Ar^1 or S_s , or Ar^2 or S_s , respectively, will have a binding group bearing an atom having one or more lone pair of electrons (e.g. an oxygen, sulphur or nitrogen atom). Preferably, one of C or S_s , Ar^1 or S_s , or Ar^2 or S_s , as appropriate, will have a binding group comprising biotin, and the other of C or S_s , Ar^1 or S_s , or Ar^2 or S_s , respectively, will have a binding group comprising avidin or streptavidin.

Alternatively, the hydrogen bond may be direct.

15 *Dipole-Dipole Bonding*

Where the bond is a dipole-dipole bond, it may be formed between permanent dipoles or between a permanent dipole and an induced dipole.

- Typically, in order to form the dipole-dipole bond, one of S_s and the compound of the invention has a permanent dipole and the other of S_s and the compound of the invention has an induced dipole or a permanent dipole, the attraction between the dipoles forming a dipole-dipole bond.


Preferably, S_s comprises binding groups (e.g. acid groups, $-(NMe_3)^+$, carboxy, carboxylate, phosphate or sulphate groups) which produce a dipole at the surface of the solid support to bind the compound of the invention.

Van der Waals Bonding

- 25 Where the bond is a van der Waals bond, the bonding is usually provided by binding groups present on C or S_s , Ar^1 or S_s , or Ar^2 or S_s , respectively.

Typically, in order to form the van der Waals bond, at least one, but preferably both, of C or S_s , Ar^1 or S_s , or Ar^2 or S_s , as appropriate, will have a hydrocarbyl or heterohydrocarbyl group (usually a large hydrocarbyl group having at least ten carbon atoms up to about 50 carbon atoms), optionally substituted with one or more A. Polyfluorinated hydrocarbyl and heterohydrocarbyl groups are particularly preferred. Typically, the hydrocarbyl or heterohydrocarbyl groups are aryl or heteroaryl groups or groups of the formula $-C(R^6)_2Ar^3$, $-C(R^6)(Ar^3)_2$ or $-C(Ar^3)_3$, where Ar^3 is independently defined the same as Ar^2 and R^6 is H, C_{1-8} hydrocarbyl, C_{1-8} hydrocarbyl substituted by one or more A, C_{1-8} heterohydrocarbyl or C_{1-8} heterohydrocarbyl substituted by one or more A.

A preferred binding group is tetrabenzofullerene (formula X).



(formula X)

Alternatively, the van der Waals bond may be direct.

Bond Cleavage

- 5 Preferably, the ions of formula (I) have a pK_{rt} value of at least zz , where zz is 0 or more (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14). More preferably, zz is 1 or more, still more preferably 2 or more, still more preferably 3 or more.

Preferably, the compounds of formula (IIa), (IIb), (IIIa) or (IIIb) or the solid supports of formula (IVai), (IVaii), (IVaiii), (IVbii), (IVbiii), (IVaiv) or (IVbiv) provide ions of formula (I') having a pK_{rt} value of at least zz , where zz is defined above.

10

C-X Bonds

The C-X bonds are cleavable by irradiation, electron bombardment, electrospray, fast atom bombardment (FAB), inductively coupled plasma (ICP) or chemical ionisation. Preferably, the C-X bonds are cleavable by irradiation or chemical ionisation.

15

The term 'irradiation' includes, for example, laser illumination, in particular as used in MALDI mass spectrometry. Laser light of about 340 nm is particularly preferred because it is typically used in MALDI mass spectrometers.

The term 'electron bombardment' includes, for example, bombardment with electrons having energy of about 70 eV.

20



Chemical ionisation can be effected, for example, by treatment with acid or acidic matrices (e.g. acidic matrices used in MALDI analysis).

Preferably group X is halogen, hydroxy, C_{1-8} hydrocarbyloxy, C_{1-8} hydrocarbyloxy substituted with one or more A, C_{1-8} heterohydrocarbyloxy, C_{1-8} heterohydrocarbyloxy substituted with one or more A, mesyl, tosyl, pentafluorophenyl, -O-succinimidyl -S-succinimidyl, or phenoxy substituted with one or more A e.g. p-nitrophenoxy. The groups pentafluorophenyl, -O-succinimidyl, -S-succinimidyl, and p-nitrophenoxy are particularly preferred.

25


Particularly preferred groups X are halogen, hydroxy, C_{1-8} hydrocarbyloxy. Especially preferred groups are hydroxy, ethoxy and chloro groups.

30 Other preferred groups X are alkyl ethers, e.g.:




Group X may also be a -Q-oligonucleotide, where Q is O, S or N(R), where R is H, C₁₋₈hydrocarbyl or C₁₋₈hydrocarbyl substituted with one or more A. Q is preferably O.

- 5 Group X may also be a nucleoside, preferably where the nucleoside is bound via its 5' end, *e.g.*:



In some embodiments of the invention, where B_p is an antibody (particularly where it is a monoclonal antibody that recognises a tumour-associated antigen), X is not:



- 10 or, optionally, X is not any other 2,6-diaminopurine nucleoside prodrug group.

In some embodiments of the invention, X is not H. If X is H, preferably at least one of Ar¹ and Ar² is polycyclic, heterocyclic or unsubstituted.

Preferred examples of group X are shown in figure 13.

Ionic C★X★ Bonds

X★ is any counterion for forming salts with compounds of the invention.

- 5 X★ includes ions having single charges and multiple charges. Typically ions having multiple charges will be associated with an appropriate number of compounds of formula (IIb), (IIIb), (IVbii), (IVbiii), (IVbiv), (Vbii), (Vbiii) or (Vbiv) in order balance the charge. Ions having multiple charges include doubly charged ions (e.g. SO_4^{2-}) and triply charged ions. X★ preferably has a single charge.

The counterion X★ may be dissociated from the derivative of formula (IIb), (IIIb), (IVbii), (IVbiii), (IVbiv), (Vbii), (Vbiii) or (Vbiv) by irradiation, electron bombardment, electrospray, fast atom bombardment (FAB), inductively coupled plasma (ICP) or chemical ionisation. Preferably, the
10 counterion X★ may be dissociated by irradiation.

When X★ is a cation, X★ is preferably H^+ .

When X★ is an anion, X★ is preferably, BF_6^- or ClO_4^- .

It is preferred that X★ is an anion.

Preferred examples of group X★ are shown in figure 13.

15 C---S_S, S_S---Ar¹ or S_S---Ar²

The C---S_S, S_S---Ar¹ or S_S---Ar² bonds are cleavable by irradiation, electron bombardment, electrospray, fast atom bombardment (FAB), inductively coupled plasma (ICP) or chemical ionisation. Preferably, the C---S_S, S_S---Ar¹ or S_S---Ar² bonds are cleavable by irradiation or chemical ionisation.

- 20 Where appropriate, the C---S_S, S_S---Ar¹ or S_S---Ar² bonds may be cleaved simultaneously or sequentially with the cleaving of the C-X bond or the dissociation of X★, as appropriate, by selection of suitable cleaving/dissociating conditions.

In one embodiment of the invention, the C---S_S bond in the solid support of formula (Vai) may be cleaved in sub-steps of step (iia) so that in a first sub-step a residue X (where X is the leaving group
25 defined above) is provided and in a second subsequent sub-step the C-X bond is cleaved thereby forming the ion of formula (I). If desired, the second sub-step may be carried out substantially (e.g. seconds, minutes, hours or even days) after the first sub-step.


Ar¹ and Ar²

Ar²


- 30 Ar² is independently an aromatic group or an aromatic group substituted with one or more A and is preferably independently cyclopropyl, cyclopropyl substituted with one or more A, aryl, aryl substituted with one or more A, heteroaryl, or heteroaryl substituted with one or more A.

Where aryl or substituted aryl, Ar² is preferably C₆₋₃₀ aryl or substituted C₆₋₃₀ aryl. Where heteroaryl or substituted heteroaryl, Ar² is preferably C₆₋₃₀ heteroaryl or substituted C₆₋₃₀ heteroaryl.

- Examples of aryl and heteroaryl are monocyclic aromatic groups (e.g. phenyl or pyridyl), fused polycyclic aromatic groups (e.g. naphthyl, such as 1-naphthyl or 2-naphthyl) and unfused polycyclic aromatic groups (e.g. monocyclic or fused polycyclic aromatic groups linked by a single bond, a double bond, or by a $-(CH=CH)_r$ linking group, where r is one or more (e.g. 1, 2, 3, 4 or 5).
- 5 Other examples of aryl groups are monovalent derivatives of aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, chrysene, coronene, fluoranthene, fluorene, *as*-indacene, *s*-indacene, indene, naphthalene, ovalene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene and rubicene, which groups may be optionally substituted by one or more A.
- Other examples of heteroaryl groups are monovalent derivatives of acridine, carbazole, β -carboline,
- 10 chromene, cinnoline, furan, imidazole, indazole, indole, indolizine, isobenzofuran, isochromene, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, thiophene and xanthene, which groups may be optionally substituted by one or more A. Preferred heteroaryl groups
- 15 are five- and six-membered monovalent derivatives, such as the monovalent derivatives of furan, imidazole, isothiazole, isoxazole, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine and thiophene. The five-membered monovalent derivatives are particularly preferred, *i.e.* the monovalent derivatives of furan, imidazole, isothiazole, isoxazole, pyrazole, pyrrole and thiophene. The heteroaryl groups may be attached to the remainder of the compound by
- 20 any carbon or hetero (e.g. nitrogen) atom.
- Ar^2 is preferably C_{6-30} aryl substituted by one or more A, preferably phenyl or naphthyl (e.g. 1-naphthyl or 2-naphthyl, especially 2-naphthyl) substituted by one or more A, more preferably phenyl substituted by one or more A. When Ar^2 is phenyl, A is preferably provided in a position ortho or para to C^\star . When Ar^2 is other than phenyl, A is preferably attached to an atom which bears the charge in at least
- 25 one of the resonance structures of the ions of formula (I).
- Fused polycyclic aromatic groups, optionally substituted with one or more A, are particularly preferred.
- A particularly preferred Ar^2 is unsubstituted pyrenyl or pyrenyl substituted with one or more A. Unsubstituted pyrenyl is preferred. The pyrenyl group may be 1-pyrenyl, 2-pyrenyl or 4-pyrenyl.
- 30 Preferred heteroaryl Ar^2 groups, whether substituted or unsubstituted, are pyridyl, pyrrolyl, thienyl and furyl, especially thienyl.
- A preferred Ar^2 group is thiophenyl or thiophenyl substituted with one or more A. Unsubstituted thiophenyl is preferred. Examples of thiophenyl are thiophen-2-yl and thiophen-3-yl, with thiophen-2-yl being especially preferred.
- 35 When substituted, Ar^2 is preferably substituted by 1, 2 or 3 A. Ar^2 is preferably:



When unsubstituted, Ar^2 is preferably:



- 5 In another preferred embodiment, Ar^2 is cyclopropyl or cyclopropyl substituted with one or more A. Unsubstituted cyclopropyl is preferred. One or more, preferably one, of Ar^2 may be cyclopropyl.

Preferred examples of group Ar^2 are shown in figures 12A and 12B.

Ar^1

- 10 Ar^1 is independently an aromatic group or an aromatic group substituted with one or more A. The definition of Ar^1 is the same as Ar^2 (as defined above), except that the valency of the group Ar^1 is adapted to accommodate the q instances of the linker L_M . Preferred Ar^2 groups are also preferred Ar^1 groups, (as defined above), except that the valency of the group Ar^1 is adapted to accommodate the q instances of the linker L_M .

- 15 When $q = 1$, Ar^1 is a divalent radical and is preferably independently cyclopropylene, cyclopropylene substituted with one or more A, arylene, arylene substituted with one or more A, heteroarylene, or heteroarylene substituted with one or more A.

Where arylene or substituted arylene, Ar^1 is preferably C_{6-30} arylene or substituted C_{6-30} arylene. Where heteroarylene or substituted heteroarylene, Ar^1 is preferably C_{6-30} heteroarylene or substituted C_{6-30} heteroarylene.

- 20 Examples of arylene and heteroarylene are monocyclic aromatic groups (e.g. phenylene or pyridylene), fused polycyclic aromatic groups (e.g. naphthylene) and unfused polycyclic aromatic groups (e.g. monocyclic or fused polycyclic aromatic groups linked by a single bond, a double bond, or by a $-(CH=CH)_r$ linking group, where r is one or more (e.g. 1, 2, 3, 4 or 5).

- 25 Other examples of arylene groups are polyvalent derivatives (where the valency is adapted to accommodate the q instances of the linker L_M) of aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, chrysene, coronene, fluoranthene, fluorene, *as*-indacene, *s*-indacene, indene,


naphthalene, ovalene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene and rubicene, which groups may be optionally substituted by one or more A.

Other examples of heteroarylene groups are polyvalent derivatives (where the valency is adapted to accommodate the q instances of the linker L_M) of acridine, carbazole, β -carboline, chromene, 5 cinnoline, furan, imidazole, indazole, indole, indolizine, isobenzofuran, isochromene, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, thiophene and xanthene, which groups may be optionally substituted by one or more A. Preferred heteroaryl groups are five- and six- 10 membered polyvalent derivatives, such as the polyvalent derivatives of furan, imidazole, isothiazole, isoxazole, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine and thiophene. The five-membered polyvalent derivatives are particularly preferred, *i.e.* the polyvalent derivatives of furan, imidazole, isothiazole, isoxazole, pyrazole, pyrrole and thiophene. The heteroaryl groups may be attached to the remainder of the compound by any carbon or hetero (*e.g.* 15 nitrogen) atom.

Ar^1 is preferably C_{6-30} arylene substituted by one or more A, preferably phenylene or naphthylene substituted by one or more A, more preferably phenylene substituted by one or more A. When Ar^1 is phenylene, A is preferably provided in a position ortho or para to C^\star . When Ar^1 is other than 20 phenylene, A is preferably attached to an atom which bears the charge in at least one of the resonance structures of the ions of formula (I).

When substituted, Ar^1 is preferably substituted by 1, 2 or 3 A.

When unsubstituted, preferred Ar^1 are:



Preferred examples of group Ar^1 are shown in figures 12A and 12B.

25 Combinations of Ar

Optionally two or three of the groups Ar^1 and Ar^2 are linked together by one or more L^5 , where L^5 is independently a single bond or a linker atom or group; and/or two or three of the groups Ar^1 and Ar^2 together form an aromatic group or an aromatic group substituted with one or more A.

When L^5 is a linker group, preferred linker groups are $-E^5-$, $-(D^5)_t-$, $-(E^5-D^5)_t-$, $-(D^5-E^5)_t-$, 30 $-E^5-(D^5-E^5)_t-$ or $-D^5-(E^5-D^5)_t-$.

D^5 is independently C_{1-8} hydrocarbylene or C_{1-8} hydrocarbylene substituted with one or more A.

E^5 is independently $-Z^5-$, $-C(=Z^5)-$, $-Z^5C(=Z^5)-$, $-C(=Z^5)Z^5-$, $-Z^5C(=Z^5)Z^5-$, $-S(=O)-$, $-Z^5S(=O)-$, $-S(=O)Z^5-$, $-Z^5S(=O)Z^5-$, $-S(=O)_2-$, $-Z^5S(=O)_2-$, $-S(=O)_2Z^5-$, $-Z^5S(=O)_2Z^5-$, where Z^5 is independently O, S or $N(R^5)$ and where R^5 is independently H, C_{1-8} hydrocarbyl or C_{1-8} hydrocarbyl substituted with one or more A. Preferably E^5 is $-O-$, $-S-$, $-C(=O)-$, $-C(=O)O-$, $-C(=S)-$, $-C(=S)O-$, $-OC(=S)-$, $-C(=O)S-$, $-SC(=O)-$, $-S(O)-$, $-S(O)_2-$, $-N(R^5)-$, $-C(=O)N(R^5)-$, $-C(=S)N(R^5)-$, $-N(R^5)C(=O)-$, $-N(R^5)C(=S)-$, $-S(=O)N(R^5)-$, $-N(R^5)S(=O)-$, $-S(=O)_2N(R^5)-$, $-N(R^5)S(=O)_2-$, $-OC(=O)O-$, $-SC(=O)O-$, $-OC(=O)S-$, $-N(R^5)C(=O)O-$, $-OC(=O)N(R^5)-$, $-N(R^5)C(=O)N(R^5)-$, $-N(R^5)C(=S)N(R^5)-$, $-N(R^5)S(=O)N(R^5)-$ or $-N(R^5)S(=O)_2N(R^5)-$.

$t' = 1$ or more, e.g. from 1 to 50, 1 to 40, 1 to 30, 1 to 20 or 1 to 10. Preferably $t' = 1, 2, 3, 4, 5, 6, 7, 8, 9$, or 10. Most preferably $t'=1$.

Where L^5 includes an atom or group which also falls within the definition of group M, the group M is preferably more reactive than the group included in L^5 .

L^5 is preferably a linker atom, preferably O or S, particularly O.


When L^5 is a linker group, a preferred L^5 is $-N(R^5)-$.

In another embodiment in which L^5 is a linker group, L^5 is $-S(=O)-$.


When two of the groups Ar^1 and Ar^2 are linked together by one or more (e.g. 2, 3 or 4) L^5 , they are preferably linked together by one L^5 , preferably O.

Preferred combinations of Ar are two Ar^2 (e.g. two Ar^2 phenyl groups) linked together by one L^5 (e.g. O or S).


Particularly preferred combinations of Ar are two Ar^2 phenyl groups, optionally substituted by one or more A (preferably unsubstituted), linked together by one L^5 (e.g. O or S), where L^5 is ortho to C^* with respect to both phenyl groups. Especially preferred combinations of two Ar^2 groups are:



In another embodiment, at least one L_M is linked to an atom or group L^5 . In this embodiment, the preferred L^5 mentioned above are, where appropriate, modified to remove substituents R^5 in order to accommodate L_M , e.g. the R^5 substituent of the ~~group~~ $-N(R^5)-$ is replaced by L_M . In this embodiment, the L^5 group to which L_M is bound is preferably:



Preferred combinations of Ar¹ and/or Ar² in this embodiment are:



When two or three of the groups Ar¹ and Ar² together form an aromatic group or an aromatic group substituted with one or more A, the aromatic group may be a carbocyclic aromatic group or a carbocyclic aromatic group in which one or more carbon atoms are each replaced by a hetero atom. Typically, in an aromatic group in which one or more carbon atoms are each replaced by a hetero atom, up to three carbons are so replaced, preferably up to two carbon atoms, more preferably one carbon atom.

Preferred hetero atoms are O, Se, S or N, more preferably O, S or N.

- 10 When two or three of the groups Ar¹ and Ar² together form an aromatic group or an aromatic group substituted with one or more A, preferred aromatic groups are C₈₋₅₀ aromatic groups.

The aromatic groups may be monocyclic aromatic groups (e.g. radicals of suitable valency derived from benzene), fused polycyclic aromatic groups (e.g. radicals of suitable valency derived from naphthalene) and unfused polycyclic aromatic groups (e.g. monocyclic or fused polycyclic aromatic groups linked by a single bond, a double bond, or by a -(CH=CH)_r- linking group, where r is one or more (e.g. 1, 2, 3, 4 or 5).


- 20 When two or three of the groups Ar¹ and Ar² together form a carbopolycyclic fused ring aromatic group, preferred groups are radicals of suitable valency obtained from naphthalene, anthracene or phenanthracene, chrysene, aceanthrylene, acenaphthylene, acephenanthrylene, azulene, fluoranthene, fluorene, *as*-indacene, *s*-indacene, indene, phenalene, and pleiadene.

When two or three of the groups Ar¹ and Ar² together form a carbopolycyclic fused ring aromatic group in which one or more carbon atoms are each replaced by a hetero atom, preferred groups are radicals of suitable polyvalency obtained from acridine, carbazole, β-carboline, chromene, cinnoline, indole, indolizine, isobenzofuran, isochromene, isoindole, isoquinoline, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyrrolizine, quinazoline, quinoline, quinolizine and quinoxaline.

Substitution of Ar¹ and Ar² – Anions and Cations

- When C★ is a cation, A is preferably an electron-donating group, including -R¹ or -Z¹R¹, where R¹ and Z¹ are defined below. Preferably, R¹ is C₁₋₈hydrocarbyl, more preferably C₁₋₈alkyl, especially methyl. Z¹ is preferably O, S or NR¹. R¹ may be substituted with one or more S_{ub}², but is preferably unsubstituted. When C★ is a cation, A is preferably -OMe, -SMe, -N(Me)₂ or Me. When C★ is a

cation, A, when an electron-donating group, is preferably provided (especially in relation to Ar¹ or Ar² being phenyl) in a position ortho or para to C★, preferably para. Furthermore, when C★ is a cation, A, when an electron-withdrawing group (*e.g.* F), is preferably provided (especially in relation to Ar¹ or Ar² being phenyl) in a position meta to C★. Thus, preferred groups Ar¹ and Ar² are as follows:



When C★ is an anion, A is preferably an electron-withdrawing group, including halogen, trihalomethyl, -NO₂, -CN, -N⁺(R¹)₂O⁻, -CO₂H, -CO₂R¹, -SO₃H, -SOR¹, -SO₂R¹, -SO₃R¹,
 10 -OC(=O)OR¹, -C(=O)H, -C(=O)R¹, -OC(=O)R¹, -C(=O)NH₂, -C(=O)NR¹₂, -N(R¹)C(=O)OR¹,
 -N(R¹)C(=O)NR¹₂, -OC(=O)NR¹₂, -N(R¹)C(=O)R¹, -C(=S)NR¹₂, -NR¹C(=S)R¹, -SO₂NR¹₂,
 -NR¹SO₂R¹, -N(R¹)C(=S)NR¹₂, or -N(R¹)SO₂NR¹₂, where R¹ is defined below. When C★ is an
 anion, A, when an electron-withdrawing group, is preferably provided (especially in relation to Ar¹
 15 or Ar² being phenyl) in a position ortho or para to C★, preferably para. Furthermore, when C★ is an
 anion, A, when an electron-donating group, is preferably provided (especially in relation to Ar¹ or
 Ar² being phenyl) in a position meta to C★.

The group A may also comprise one or more isotopes of the atoms making up group A (*e.g.* example 60), thus, as discussed in more detail below, allowing the masses of the compounds of the invention to be varied. Preferred isotopes are ¹³C, ¹⁸O and ²H. When providing a series of compounds which
 20 differ only in their masses, ¹³C and ¹⁸O are particularly preferred as ²H atoms may cause a substantial change in the chemical properties of the compound due to the kinetic isotope effect.

Solid Supports

'Solid supports' for use with the invention include polymer beads, metals, resins, columns, surfaces (including porous surfaces) and plates (*e.g.* mass-spectrometry plates).

25 The solid support is preferably one suitable for use in a mass spectrometer, such that the invention can be conveniently accommodated into existing MS apparatus. Ionisation plates from mass spectrometers are thus preferred solid supports, *e.g.* gold, glass-coated or plastic-coated plates. Solid gold supports are particularly preferred.

Resins or columns, such as those used in affinity chromatography and the like, are particularly useful
 30 for receiving solutions of biopolymers (purified or mixtures). For example, a cellular lysate could be passed through such a column of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv) followed by cleavage of the support to leave compounds of formula (I).

Solid supports of formulae (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv) will generally present exposed groups M capable of reacting with a biopolymer, B_p. For MS analysis, ions preferably have a predictable mass to charge (m/e) ratio. If a biopolymer reacts with more than one M group, however, then it will carry more than one positive charge once ionised, and its m/e ratio will decrease. Advantageously, therefore, the groups M are arranged such that any biopolymer molecule will covalently link with only a single group M. Consequently, each biopolymer will, on ionisation, carry a single positive charge and thus have a predictable mass to charge ratio.

Typically, the surface density of the solid supports of (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv) will be provided so that a biopolymer molecule can only covalently link with one group M and thus to prevent the formation of multiply derivatised biopolymers.

Varying the mass of compounds of the invention

Within the general formulae (I), (IIa), (IIb), (IIIa), (IIIb), (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii), (IVbiv), (Vai), (Vaii), (Vaiii), (Vaiv), (Vbii), (Vbiii) and (Vbiv), there is much scope for variation. There is thus much scope of variation in the mass of these compounds. In some embodiments of the invention, it is preferred to use a series of two or more (e.g. 2, 3, 4, 5, 6 or more) compounds with different and defined molecular masses.

The masses of the compounds of the invention can be varied via L_M, Ar¹ and/or Ar². Preferably, the masses of the compounds of the invention are varied by varying A on the groups Ar¹ and/or Ar².

In this aspect of invention, compounds of the invention advantageously comprise one or more of F or I as substituents A of the groups Ar¹, Ar² or Ar³. F and I each only have one naturally occurring isotope, ¹⁹F and ¹²⁷I respectively, and thus by varying the number of F and I atoms present in the structure of the compounds, can provide a series of molecular mass labels having substantially identical shaped peaks on a mass spectrum.

Compounds of the invention may also include one or more ²H atoms, preferably as a substituent A or a part thereof of the groups L_M, Ar¹, Ar² or Ar³ (in particular L_M), in order to vary the masses of the compounds of the invention. The compounds of the invention may include isotopes of ¹³C and ¹⁸O, preferably as a substituent A or a part thereof of the groups L_M, Ar¹, Ar² or Ar³ (in particular Ar¹, Ar² or Ar³), in order to vary the masses of the compounds of the invention. Compounds comprising ²H, ¹³C and ¹⁸O may also be used to provide a series of molecular mass labels having substantially identical shaped peaks on a mass spectrum, by varying the number of ²H, ¹³C and ¹⁸O atoms present in the structure of the compounds. When providing a series of compounds which differ only in their masses, ¹³C and ¹⁸O are particularly preferred as ²H atoms may cause a substantial change in the chemical properties of the compound due to the kinetic isotope effect.

In order to increase the molecular mass of the compounds of the invention and to increase the number of available sites for substitution by A, especially F and I, one or more of Ar¹ and Ar² may

be substituted by one or more dendrimer radicals of appropriate valency, either as substituent A or group L_M .

Preferred dendrimer radicals are the radicals obtained from the dendrimers of US 6,455,071 and PAMAM dendrimers.

- 5 The compounds of the invention may advantageously be used in the method of analysing a biopolymer disclosed herein, in particular in a method for following a reaction involving a biopolymer, B_P , since the abundance of a species of may be determined by mass spectrometry by measuring the intensity of the relevant peak in an obtained mass spectrum.

Specifically, there is provided a method for analysing biopolymer B_P , comprising the steps of:

- 10 (i) reacting a first sample comprising biopolymer B_P with a compound of formula (IIa) or (IIb) or a solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv) at a time t_1 ;
- (ii) reacting a second sample comprising biopolymer B_P with a compound of formula (IIa) or (IIb) or a solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv)
- 15 at a later time t_2 ;
- (iii) preparing and analysing cations of formula (I) from the first and second samples; and
- (iv) comparing the results of the analysis from step (iii).

If levels of the biopolymer B_P decrease between times t_1 and t_2 then there will be a decrease in detected ion; if levels of the biopolymer B_P increase between times t_1 and t_2 then there will be an

20 increase in detected ion. The effects of stimuli on transcription and/or translation can therefore be monitored.

Advantageously, different compounds of formula (IIa) or (IIb) or different solid supports of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv) are used at different times in order to facilitate simultaneous and parallel analysis of the first and second samples. For example, if the two

25 compounds used at times t_1 and t_2 differ only by a 1H to ^{19}F substitution then the relative abundance of B_P at the two times can be determined by comparing peaks separated by 18 units.

Advantageously, the reaction of the biopolymer with the compound of formula (IIa) or (IIb) or the solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv) will fix the biopolymer to prevent it reacting further and the steps of providing and analysing the cations may be

30 carried out at a later convenient time. Alternatively, if the reaction of the biopolymer with the compound of formula (IIa) or (IIb) or the solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv) does not quench the reaction of the biopolymer being followed, a cation of formula (I) from the reaction product of step (i) or step (v) should be obtained as soon as possible after reaction of the biopolymer with the compound of formula (IIa) or (IIb) or the solid support of

35 formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv).

Compounds of Formulae (IIa) and (IIb)

The compounds of formulae (IIa) or (IIb) are available commercially or may be synthesised by known techniques.


Commercially available compounds of formulae (IIa) or (IIb) are disclosed, for example in the Molecular Probes Catalogue, 2002. Commercially available trityls, and derivatives and analogues thereof, may also be derivatised with the groups $(L_M\{M\}_p)_q$ by known techniques.








Methods for synthesis of compounds of formula (IIa) or (IIb) useful in the present invention are described in Chem. Soc. Rev. (2003) 32, p. 3-13, scheme 2 and "1. introduction", last two paragraphs. Groups $(L_M\{M\}_p)_q$ are usually introduced into the intermediates and the compounds are then assembled using the appropriate pathways. Alternatively, the groups $(L_M\{M\}_p)_q$ may be added after assembly of the aromatic groups and α -carbon of the compounds.


Methods for synthesis of compounds of formulae (IIa) or (IIb) are also described in WO99/60007.

Further methods for synthesising the compounds of formulae (IIa) or (IIb) are described in the co-pending European patent application entitled "Derivatised Molecules for Mass Spectrometry" having the same filing date as this application.

Preferred compounds of formula (IIa), (IIb) and (IVai) are:







Chemical Groups

The ions of the invention are stabilised by the resonance effect of the aromatic groups Ar^1 and Ar^2 . The term 'C★' is a carbon atom bearing a single positive charge or a single negative charge' therefore not only includes structures having the charge localised on the carbon atom but also resonance structures in which the charge is delocalised from the carbon atom.

The term 'linker atom or group' includes any divalent atom or divalent group.

The term 'aromatic group' includes quasi and/or pseudo-aromatic groups, *e.g.* cyclopropyl and cyclopropylene groups.

- 10 The term 'halogen' includes fluorine, chlorine, bromine and iodine.

The term 'hydrocarbyl' includes linear, branched or cyclic monovalent groups consisting of carbon and hydrogen. Hydrocarbyl groups thus include alkyl, alkenyl and alkynyl groups, cycloalkyl (including polycycloalkyl), cycloalkenyl and aryl groups and combinations thereof, *e.g.* alkylcycloalkyl, alkylpolycycloalkyl, alkylaryl, alkenylaryl, cycloalkylaryl, cycloalkenylaryl, cycloalkylalkyl, polycycloalkylalkyl, arylalkyl, arylalkenyl, arylcycloalkyl and arylcycloalkenyl groups. Preferred hydrocarbyl are C_{1-14} hydrocarbyl, more preferably C_{1-8} hydrocarbyl.

Unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, *e.g.* arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.

- 20 The term 'hydrocarbylene' includes linear, branched or cyclic divalent groups consisting of carbon and hydrogen formally made by the removal of two hydrogen atoms from the same or different (preferably different) skeletal atoms of the group. Hydrocarbylene groups thus include alkylene, alkenylene and alkynylene groups, cycloalkylene (including polycycloalkylene), cycloalkenylene and arylene groups and combinations thereof, *e.g.* alkylene-cycloalkylene, alkylene-polycycloalkylene, alkylene-arylene, alkenylene-arylene, cycloalkylene-alkylene, polycycloalkylene-alkylene, arylene-alkylene and arylene-alkenylene groups. Preferred hydrocarbylene are C_{1-14} hydrocarbylene, more preferably C_{1-8} hydrocarbylene.

The term 'hydrocarbyloxy' means hydrocarbyl-O-.

The terms 'alkyl', 'alkylene', 'alkenyl', 'alkenylene', 'alkynyl', or 'alkynylene' are used herein to refer to both straight, cyclic and branched chain forms. Cyclic groups include C₃₋₈ groups, preferably C₅₋₈ groups.

5 The term 'alkyl' includes monovalent saturated hydrocarbyl groups. Preferred alkyl are C₁₋₈, more preferably C₁₋₄ alkyl such as methyl, ethyl, n-propyl, i-propyl or t-butyl groups.

Preferred cycloalkyl are C₅₋₈ cycloalkyl.

The term 'alkoxy' means alkyl-O-.

The term 'alkenyl' includes monovalent hydrocarbyl groups having at least one carbon-carbon double bond and preferably no carbon-carbon triple bonds. Preferred alkenyl are C₂₋₄ alkenyl.

10 The term 'alkynyl' includes monovalent hydrocarbyl groups having at least one carbon-carbon triple bond and preferably no carbon-carbon double bonds. Preferred alkynyl are C₂₋₄ alkynyl.

The term 'aryl' includes monovalent aromatic groups, such as phenyl or naphthyl. In general, the aryl groups may be monocyclic or polycyclic fused ring aromatic groups. Preferred aryl are C₆-C₁₄aryl.

15 Other examples of aryl groups are monovalent derivatives of aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, chrysene, coronene, fluoranthene, fluorene, *as*-indacene, *s*-indacene, indene, naphthalene, ovalene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene and rubicene.

The term 'alkylene' includes divalent saturated hydrocarbylene groups. Preferred alkylene are C₁₋₄ alkylene such as methylene, ethylene, n-propylene, i-propylene or t-butylene groups.

20 Preferred cycloalkylene are C₅₋₈ cycloalkylene.

The term 'alkenylene' includes divalent hydrocarbylene groups having at least one carbon-carbon double bond and preferably no carbon-carbon triple bonds. Preferred alkenylene are C₂₋₄ alkenylene.

The term 'alkynylene' includes divalent hydrocarbylene groups having at least one carbon-carbon triple bond and preferably no carbon-carbon double bonds. Preferred alkynylene are C₂₋₄ alkynylene.

25 The term 'arylene' includes divalent aromatic groups, such as phenylene or naphthylene. In general, the arylene groups may be monocyclic or polycyclic fused ring aromatic groups. Preferred arylene are C₆-C₁₄arylene.

30 Other examples of arylene groups are divalent derivatives of aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, chrysene, coronene, fluoranthene, fluorene, *as*-indacene, *s*-indacene, indene, naphthalene, ovalene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene and rubicene.

The term 'heterohydrocarbyl' includes hydrocarbyl groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N. Heterohydrocarbyl groups thus include

- heteroalkyl, heteroalkenyl and heteroalkynyl groups, cycloheteroalkyl (including polycycloheteroalkyl), cycloheteroalkenyl and heteroaryl groups and combinations thereof, *e.g.* heteroalkylcycloalkyl, alkylcycloheteroalkyl, heteroalkylpolycycloalkyl, alkylpolycycloheteroalkyl, heteroalkylaryl, alkylheteroaryl, heteroalkenylaryl, alkenylheteroaryl, cycloheteroalkylaryl, cycloalkylheteroaryl, heterocycloalkenylaryl, cycloalkenylheteroaryl, cycloalkylheteroalkyl, cycloheteroalkylalkyl, polycycloalkylheteroalkyl, polycycloheteroalkylalkyl, arylheteroalkyl, heteroarylalkyl, arylheteroalkenyl, heteroarylalkenyl, arylcycloheteroalkyl, heteroarylalkyl, arylheterocycloalkenyl and heteroarylalkyl groups. The heterohydrocarbyl groups may be attached to the remainder of the compound by any carbon or hetero (*e.g.* nitrogen) atom.
- 10 The term 'heterohydrocarbylene' includes hydrocarbylene groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N. Heterohydrocarbylene groups thus include heteroalkylene, heteroalkenylene and heteroalkynylene groups, cycloheteroalkylene (including polycycloheteroalkylene), cycloheteroalkenylene and heteroarylene groups and combinations thereof,
- 15 *e.g.* heteroalkylenecycloalkylene, alkylenecycloheteroalkylene, heteroalkylenepolycycloalkylene, alkylenepolycycloheteroalkylene, heteroalkylenearylene, alkyleneheteroarylene, heteroalkenylenearylene, alkenyleneheteroarylene, cycloalkyleneheteroalkylene, cycloheteroalkylenealkylene, polycycloalkyleneheteroalkylene, polycycloheteroalkylenealkylene, aryleneheteroalkylene, heteroarylenealkylene, aryleneheteroalkenylene, heteroarylenealkenylene
- 20 groups. The heterohydrocarbylene groups may be attached to the remainder of the compound by any carbon or hetero (*e.g.* nitrogen) atom.

Where reference is made to a carbon atom of a hydrocarbyl or other group being replaced by an O, S, Se or N atom, what is intended is that:



- 25 —CH= is replaced by —N= ; or
 $\text{—CH}_2\text{—}$ is replaced by —O— , —S— or —Se— .

The term 'heteroalkyl' includes alkyl groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N.

- 30 The term 'heteroalkenyl' includes alkenyl groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N.

The term 'heteroalkynyl' includes alkynyl groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or

- 35 N, preferably O, S or N.

The term 'heteroaryl' includes aryl groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N. Preferred heteroaryl are C₅₋₁₄heteroaryl. Examples of heteroaryl are pyridyl, pyrrolyl, thienyl or furyl.

- 5 Other examples of heteroaryl groups are monovalent derivatives of acridine, carbazole, β -carboline, chromene, cinnoline, furan, imidazole, indazole, indole, indolizine, isobenzofuran, isochromene, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, thiophene and
- 10 xanthene. Preferred heteroaryl groups are five- and six-membered monovalent derivatives, such as the monovalent derivatives of furan, imidazole, isothiazole, isoxazole, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine and thiophene. The five-membered monovalent derivatives are particularly preferred, *i.e.* the monovalent derivatives of furan, imidazole, isothiazole, isoxazole, pyrazole, pyrrole and thiophene.
- 15 The term 'heteroalkylene' includes alkylene groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N.

The term 'heteroalkenylene' includes alkenylene groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced

20 independently by O, S, Se or N, preferably O, S or N.

The term 'heteroalkynylene' include alkynylene groups in which up to three carbon atoms, preferably up to two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N.

The term 'heteroarylene' includes arylene groups in which up to three carbon atoms, preferably up to

25 two carbon atoms, more preferably one carbon atom, are each replaced independently by O, S, Se or N, preferably O, S or N. Preferred heteroarylene are C₅₋₁₄heteroarylene. Examples of heteroarylene are pyridylene, pyrrolylene, thienylene or furylene.

Other examples of heteroarylene groups are divalent derivatives (where the valency is adapted to accommodate the q instances of the linker L_M) of acridine, carbazole, β -carboline, chromene,

30 cinnoline, furan, imidazole, indazole, indole, indolizine, isobenzofuran, isochromene, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, thiophene and xanthene. Preferred heteroarylene groups are five- and six-membered divalent derivatives, such as the divalent

35 derivatives of furan, imidazole, isothiazole, isoxazole, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine and thiophene. The five-membered divalent derivatives are

particularly preferred, *i.e.* the divalent derivatives of furan, imidazole, isothiazole, isoxazole, pyrazole, pyrrole and thiophene.

Substitution

A is independently a substituent, preferably a substituent S_{ub}^1 . Alternatively, A may be 2H .

- 5 S_{ub}^1 is independently halogen, trihalomethyl, $-NO_2$, $-CN$, $-N^+(R^1)_2O^-$, $-CO_2H$, $-CO_2R^1$, $-SO_3H$, $-SOR^1$, $-SO_2R^1$, $-SO_3R^1$, $-OC(=O)OR^1$, $-C(=O)H$, $-C(=O)R^1$, $-OC(=O)R^1$, $-NR^1_2$, $-C(=O)NH_2$, $-C(=O)NR^1_2$, $-N(R^1)C(=O)OR^1$, $-N(R^1)C(=O)NR^1_2$, $-OC(=O)NR^1_2$, $-N(R^1)C(=O)R^1$, $-C(=S)NR^1_2$, $-NR^1C(=S)R^1$, $-SO_2NR^1_2$, $-NR^1SO_2R^1$, $-N(R^1)C(=S)NR^1_2$, $-N(R^1)SO_2NR^1_2$, $-R^1$ or $-Z^1R^1$.

Z^1 is O, S, Se or NR^1 .

- 10 R^1 is independently H, C_{1-8} hydrocarbonyl, C_{1-8} hydrocarbonyl substituted with one or more S_{ub}^2 , C_{1-8} heterohydrocarbonyl or C_{1-8} heterohydrocarbonyl substituted with one or more S_{ub}^2 .

S_{ub}^2 is independently halogen, trihalomethyl, $-NO_2$, $-CN$, $-N^+(C_{1-6}alkyl)_2O^-$, $-CO_2H$, $-CO_2C_{1-6}alkyl$, $-SO_3H$, $-SOC_{1-6}alkyl$, $-SO_2C_{1-6}alkyl$, $-SO_3C_{1-6}alkyl$, $-OC(=O)OC_{1-6}alkyl$, $-C(=O)H$, $-C(=O)C_{1-6}alkyl$, $-OC(=O)C_{1-6}alkyl$, $-N(C_{1-6}alkyl)_2$, $-C(=O)NH_2$, $-C(=O)N(C_{1-6}alkyl)_2$,

- 15 $-N(C_{1-6}alkyl)C(=O)O(C_{1-6}alkyl)$, $-N(C_{1-6}alkyl)C(=O)N(C_{1-6}alkyl)_2$, $-OC(=O)N(C_{1-6}alkyl)_2$, $-N(C_{1-6}alkyl)C(=O)C_{1-6}alkyl$, $-C(=S)N(C_{1-6}alkyl)_2$, $-N(C_{1-6}alkyl)C(=S)C_{1-6}alkyl$, $-SO_2N(C_{1-6}alkyl)_2$, $-N(C_{1-6}alkyl)SO_2C_{1-6}alkyl$, $-N(C_{1-6}alkyl)C(=S)N(C_{1-6}alkyl)_2$, $-N(C_{1-6}alkyl)SO_2N(C_{1-6}alkyl)_2$, $C_{1-6}alkyl$ or $-Z^1C_{1-6}alkyl$.

Where reference is made to a substituted group, the substituents are preferably from 1 to 5 in number,

- 20 most preferably 1.

However, molecular mass labels of the invention will generally comprise 1 or more, typically between 1 and 100 (*e.g.* 1 to 50, preferably 1 to 20) substituents S_{ub}^1 or S_{ub}^2 , typically F or I, in order to vary the masses of the molecular mass labels.

Preferred examples of substituent A are shown in figure 14.

25 Miscellaneous

A may optionally be a monovalent dendrimer radical or a monovalent dendrimer radical substituted with one or more substituents S_{ub}^1 .

General

- 30 The term "comprising" means "including" as well as "consisting" *e.g.* a composition "comprising" X may consist exclusively of X or may include something additional *e.g.* X + Y.

The term "about" in relation to a numerical value x means, for example, $x \pm 10\%$.

The word "substantially" does not exclude "completely" *e.g.* a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.

Table 1 — C★ is a cation

Formula	Structure
Formula (I)	$(\text{Ar}^2)_n - \overset{\oplus}{\text{C}} - [\text{Ar}^1 - (\text{L}_M - \{\text{M}' - \text{B}_P'\}_p)_q]_m$
Formula (IIb)	$(\text{Ar}^2)_n - \overset{\oplus}{\text{C}} - [\text{Ar}^1 - (\text{L}_M - \{\text{M}\}_p)_q]_m$ X^\ominus
Formula (IIIb)	$(\text{Ar}^2)_n - \overset{\oplus}{\text{C}} - [\text{Ar}^1 - (\text{L}_M - \{\text{M}' - \text{B}_P'\}_p)_q]_m$ X^\ominus
Formula (IVbii)	$ \begin{array}{c} \textcircled{\text{S}_S} \\ \vdots \\ \text{Ar}^1 - (\text{L}_M - \{\text{M}\}_p)_q \\ \\ (\text{Ar}^2)_n - \overset{\oplus}{\text{C}} - [\text{Ar}^1 - (\text{L}_M - \{\text{M}\}_p)_q]_{m-1} \end{array} $ X^\ominus
Formula (IVbiii)	$ \begin{array}{c} \textcircled{\text{S}_S} \\ \vdots \\ \text{Ar}^2 \\ \\ (\text{Ar}^2)_{n-1} - \overset{\oplus}{\text{C}} - [\text{Ar}^1 - (\text{L}_M - \{\text{M}\}_p)_q]_m \end{array} $ X^\ominus
Formula (IVbiv)	$ \begin{array}{c} \{\text{M}\}_{p-1} \text{L}_M \text{M}'' - \textcircled{\text{S}_S} \\ \\ \text{Ar}^1 - (\text{L}_M \{\text{M}\}_p)_{q-1} \\ \\ (\text{Ar}^2)_n - \overset{\oplus}{\text{C}} - [\text{Ar}^1 - (\text{L}_M \{\text{M}\}_p)_q]_{m-1} \end{array} $ X^\ominus
Formula (Vbii)	$ \begin{array}{c} \textcircled{\text{S}_S} \\ \vdots \\ \text{Ar}^1 - (\text{L}_M \{\text{M}' - \text{B}_P'\}_p)_q \\ \\ (\text{Ar}^2)_n - \overset{\oplus}{\text{C}} - [\text{Ar}^1 - (\text{L}_M \{\text{M}' - \text{B}_P'\}_p)_q]_{m-1} \end{array} $ X^\ominus

Formula (Vbiii)	$ \begin{array}{c} \text{S}_8 \\ \vdots \\ \text{Ar}^2 \\ \\ (\text{Ar}^2)_{n-1}-\text{C}-[\text{Ar}^1-(\text{L}_M-\{\text{M}'-\text{B}_{\text{P}}'\}_p)_q]_m \\ \oplus \\ \text{X}^\ominus \end{array} $
Formula (Vbiv)	$ \begin{array}{c} \{\text{B}_{\text{P}}'-\text{M}'\}_{p-1}\text{L}_M\{\text{M}'-\text{B}_{\text{P}}'\} \\ \\ \text{Ar}^1-(\text{L}_M\{\text{M}'-\text{B}_{\text{P}}'\}_p)_{q-1} \\ \\ (\text{Ar}^2)_n-\text{C}-[\text{Ar}^1-(\text{L}_M\{\text{M}'-\text{B}_{\text{P}}'\}_p)_q]_{m-1} \\ \oplus \\ \text{X}^\ominus \end{array} $

Table 2 — $n = 2, m = 1, p = 1$ and $q = 1$

Formula	Structure
Formula (I)	$ \begin{array}{c} \text{Ar}^2 \\ \\ \text{Ar}^2-\text{C}-\text{Ar}^1-\text{L}_M\text{M}'-\text{B}_{\text{P}}' \\ \star \end{array} $
Formula (IIa)	$ \begin{array}{c} \text{Ar}^2 \\ \\ \text{Ar}^2-\text{C}-\text{Ar}^1-\text{L}_M\text{M} \\ \\ \text{X} \end{array} $
Formula (IIb)	$ \begin{array}{c} \text{Ar}^2 \\ \\ \text{Ar}^2-\text{C}-\text{Ar}^1-\text{L}_M\text{M} \\ \star \\ \text{X}\star \end{array} $
Formula (IIIa)	$ \begin{array}{c} \text{Ar}^2 \\ \\ \text{Ar}^2-\text{C}-\text{Ar}^1-\text{L}_M\text{M}'-\text{B}_{\text{P}}' \\ \\ \text{X} \end{array} $
Formula (IIIb)	$ \begin{array}{c} \text{Ar}^2 \\ \\ \text{Ar}^2-\text{C}-\text{Ar}^1-\text{L}_M\text{M}'-\text{B}_{\text{P}}' \\ \star \\ \text{X}\star \end{array} $
Formula (IVai)	$ \begin{array}{c} \text{Ar}^2 \\ \\ \text{Ar}^2-\text{C}-\text{Ar}^1-\text{L}_M\text{M} \\ \vdots \\ \text{S}_8 \end{array} $

Formula (IVaii)	$ \begin{array}{c} \textcircled{\text{S}_s} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M} \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \\ \text{X} \end{array} $
Formula (IVaiii)	$ \begin{array}{c} \textcircled{\text{S}_s} \text{---} \text{Ar}^2 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M} \\ \\ \text{X} \end{array} $
Formula (IVaiv)	$ \begin{array}{c} \text{L}_M \text{M}'' \text{---} \textcircled{\text{S}_s} \\ \\ \text{Ar}^1 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \\ \text{X} \end{array} $
Formula (IVbii)	$ \begin{array}{c} \textcircled{\text{S}_s} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M} \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \star \\ \text{X} \star \end{array} $
Formula (IVbiii)	$ \begin{array}{c} \textcircled{\text{S}_s} \text{---} \text{Ar}^2 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M} \\ \star \\ \text{X} \star \end{array} $
Formula (IVbiv)	$ \begin{array}{c} \text{L}_M \text{M}'' \text{---} \textcircled{\text{S}_s} \\ \\ \text{Ar}^1 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \star \\ \text{X} \star \end{array} $
Formula (Vai)	$ \begin{array}{c} \text{Ar}^2 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M}' \text{---} \text{B}_P' \\ \\ \textcircled{\text{S}_s} \end{array} $

Formula (Vaii)	$ \begin{array}{c} \textcircled{S_S} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M}' \text{---} \text{Bp}' \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \\ \text{X} \end{array} $
Formula (Vaiii)	$ \begin{array}{c} \textcircled{S_S} \text{---} \text{Ar}^2 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M}' \text{---} \text{Bp}' \\ \\ \text{X} \end{array} $
Formula (Vaiv)	$ \begin{array}{c} \text{L}_M \text{M}' \text{---} \text{Bp}' \\ \\ \text{Ar}^1 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \\ \text{X} \end{array} $
Formula (Vbii)	$ \begin{array}{c} \textcircled{S_S} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M}' \text{---} \text{Bp}' \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \star \\ \text{X} \star \end{array} $
Formula (Vbiii)	$ \begin{array}{c} \textcircled{S_S} \text{---} \text{Ar}^2 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^1 \text{---} \text{L}_M \text{M}' \text{---} \text{Bp}' \\ \star \\ \text{X} \star \end{array} $
Formula (Vbiv)	$ \begin{array}{c} \text{L}_M \text{M}' \text{---} \text{Bp}' \\ \\ \text{Ar}^1 \\ \\ \text{Ar}^2 \text{---} \text{C} \text{---} \text{Ar}^2 \\ \star \\ \text{X} \star \end{array} $

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 demonstrates conceptually the effect of the signal on a mass spectrum by a compound of formula (IIa) or (IIb) of the invention. Free biopolymer, such as a peptide, has poorer desorption properties characterised by a smaller peak on the left of mass-spectrum whereas desorption improves when the same molecule is conjugated to a compound of the invention.

Figure 2 shows the steps of biopolymer with a compound of formula (IVai). The derivatisation of a biopolymer with a compound of the invention can be carried out more conveniently by utilising the solid phase-based format, whereby the compound is temporarily covalently attached to a solid support. This eliminates all the separation steps associated with homogenous approach as the only additional step required would be a washing step. The solid support can be a resin, a surface or a porous surface. Alternatively, the solid support may be a mass-spectrometry sample plate, which dramatically decreases the sample preparation time. Both gold, glass- and plastic-coated plates are compatible with this approach.

Figure 3 shows the steps of 'reverse' biopolymer derivatisation on a covalent solid support whereby the release of the biopolymer derivative happens simultaneously with the derivatisation process. The process is applicable M groups involving leaving groups.

Figure 4 shows the steps of biopolymer derivatisation on an ionic solid support.

Figure 5 shows of the steps of solid support-assisted biopolymer derivatisation. The biopolymer is first trapped onto a solid support and then labelled with a compound of formula (IIa) or (IIb). An advantage of this technique is that a preliminary sample enrichment occurs, since not all of the biopolymer in the sample will stick to the solid support surface.

Figure 6 shows the mass spectrum obtained when analysing an Gly-Gly-O-acyl dipeptide conjugated with a trityl compound of the invention.

Figure 7 shows the mass spectrum obtained when analysing a conjugate of a peptide with a trityl compound of the invention.

Figure 8 compared the mass spectra of a BSA digest without (8A) and with (8B) labelling.

Figure 9 shows the mass spectrum obtained when analysing a mixture of trityl-labelled amines.

Figures 10A and 10B show preferred examples of group L_M .

Figures 11A and 11B show preferred examples of group M.

Figures 12A and 12B shows preferred examples of groups Ar^1 and Ar^2 .

Figure 13 shows preferred examples of groups X and X^\star .

Figure 14 shows preferred examples of substituent group A.

MODES FOR CARRYING OUT THE INVENTION

Materials and Methods

The solid supports were Tenta Gel Macrobeads OH and NH_2 , 280-320 microns, Rapp Polymer. (MA)LDI-TOF mass-spectra were recorded on a PE-ABI VoyagerTM Elite Reflectron Delayed Extraction Instrument. TLC were carried out with Merck silica gel (Kieselgel 60 F₂₅₄ precoated plates and Kieselgel 60 0.040–0.063 mm). HPLC was carried out on a Waters system (Milford, MA,

USA). Phosphoroamidite couplings were carried out in an ABI 394 DNA/RNA synthesiser. Chemicals and solvents were from Sigma/Aldrich/Fluka (USA), and BDH/Merck.

Example 1 — Conjugation of a trityl tag (in solution phase) with solid support-bound biopolymer

5 A 15mer poly-T oligonucleotide was synthesised on an ABI 394 DNA synthesiser using a T CPG support according to standard protocols of phosphoramidite chemistry on 0.2 μ mol scale. After the last coupling, a MMTr-protected 'aminolink' phosphoramidite (Glen Res., USA) was added to a growing chain and deprotected using standard deblocker (2% DCA in DCM). The column was removed from the synthesiser, and after 10 min wash with acetonitrile it was attached to two 5 ml syringes and washed with a 0.1M solution of NHS-activated 4,4'-dimethoxy-4"-carboxyethyl trityl
10 for 10 min at RT. The column was then washed with (3 x 10 ml) acetonitrile, placed on a DNA synthesiser and deprotected with ammonia according to standard protocols. The residue obtained after the evaporation was dissolved in 0.1 ml of 2M LiClO₄ and precipitated from cold acetone (1.5 ml). The precipitate was washed with 0.5ml of acetone and dried.

Example 2 — Homogenous conjugation of a trityl with non-polymeric ligands

15 A solution of NHS-activated 4,4'-dimethoxy-4"-carboxyethyl trityl (0.1M) in THF/dioxane (1:1) was mixed with a solution (0.5-1M) of an amine or of a mixture of amines (for example, propyl amine, butyl amine, pentyl amine, hexyl amine and phenethyl amine), typically 10 ml of a solution of an activated trityl with 5 ml of an amine solution. The mixtures were purified on prep-TLC (2mm-thick glass plates with UV254 indicator, Analtech/Aldrich-Sigma), typically in chloroform with 0.5%
20 triethylamine. The areas containing the desired products were scratched off the plate, and the conjugates or the mixtures thereof were eluted using same solvent with 2-5% MeOH, filtered through a layer of glass wool, evaporated and dried.

Example 3 — Homogenous conjugation of a nhs-activated trityl with polymeric ligands

A peptide, an oligonucleotide, or any other biopolymer containing a (primary) amino group, is
25 dissolved in a mixture of water and acetonitrile depending on its solubility, typically 20-50% of water in CH₃CN. Non-aminogroup-containing buffers (ie. 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2, or a bicarbonate buffer, but an additional desalting step may then need to be introduced to cut off the metal ions prior to mass-spectrometry) can be used to keep the pH at between 7-9. For particularly poorly soluble ligands other solvents may be used such as THF, DMSO, etc.
30 A solution of NHS-activated 4,4'-dimethoxy-4"-carboxyethyl trityl in acetonitrile or THF is added in approx. 5-10 times excess compared to an amine component. Conjugation usually reaches the maximum yield over 2-4 hours of reaction time. The conjugate formed can be analysed by MS directly, or after HPLC-purification.

Example 4 — Conjugation of a solid phase-immobilised nhs-activated trityl tag with a ligand

35 A Solid Phase-Immobilised NHS-Activated Trityl Tag was prepared by either method 1 or method 2.

Method 1: A NHS-Activated 4,4'-dimethoxy-4"-carboxyethyl trityl tag was covalently attached to hydroxyl groups of 200 µm Rapp Polymer beads by shaking the suspension of 100 mg of the resin in 5 ml of 0.1 M solution of trityl chloride tag in dry pyridine at +4°C for 3 hours and then washing the resin with pyridine and acetonitrile and drying *in vacuo*.

- 5 **Method 2.** A 5'-tritylated thymidine phosphoramidite was prepared from NHS-activated 4,4'-dimethoxy-4"-carboxyethyl trityl chloride in a standard way [M.J. Gait, Oligonucleotide Synthesis: A Practical Approach, IRL, Oxford, 1984]. The Rapp Polymer beads (2 x 40 mg) were placed in two 1 micromol scale DNA synthesis columns (Glen Res.). The first column was coupled with the said phosphoramidite on an ABI DNA synthesiser using manual supply of reagents (0.1M solution of a
10 phosphoramidite and other standard phosphoramidite synthesis reagents) with a coupling step of 15 min. The second column was first derivatised with a trebler phosphoramidite (Glen Res.) according to the manufacturer's protocols and then coupled with the trityl tag-containing phosphoramidite as described for the first column. Both columns were excessively washed with acetonitrile.

The trityl loading of the solid supports produced by either method was determined
15 spectrophotometrically (absorbance measurements at 490nm) to be 0.21 mmol/g for a straight attachment and 0.39 mmol/g for a tritylation on top of the trebling synthon. (The hydroxyl group loading of the Rapp polymer used was 0.25mmol/g).

To the solid support prepared as described above, a mixture of compounds to be labelled (typically peptides) is added, typically in a mixture of 20-50% water in acetonitrile. After incubation, with
20 occasional shaking, for 60-120 min the resin is washed with several volumes of the same solvent, and the conjugated products are cleaved off the resin, typically by adding 0.5-2% TFA in appropriate solvent. The collected sample is then analysed by MS.

Example 5 — Mass spectrometry analysis of a derivatised Gly-Gly dipeptide

Figure 6 shows the mass spectrum obtained from a compound of the invention comprising a
25 derivatised Gly-Gly-O-acyl dipeptide biopolymer.

The ion of formula (I) containing the derivatised Gly-Gly-O-acyl biopolymer is observed at the peak at molecular weight 516.5. There was no peak corresponding to the free dipeptide.

The fragment of formula (VI), in which the derivatised Gly-Gly-O-acyl biopolymer has been lost, is observed at the peak at the molecular weight 374.6.

30 **Example 6 — Mass spectrometry analysis of a derivatised peptide**

Figure 7 shows the mass spectrum obtained from a compound of the invention comprising a derivatised peptide biopolymer. The free peptide had a molecular weight of 310.

The ion of formula (I) containing the derivatised peptide biopolymer is observed at the peak at molecular weight 665.0.

The fragment of formula (VI), in which the derivatised peptide has been lost, is observed at the peak at the molecular weight 375.0.

Significantly, there is only a very small peak at molecular weight 310, where a peak corresponding to the free biopolymer would be found. The relative size of the peaks at 665.0 and 310 thus demonstrate the significantly improved ionisability of the compounds of the invention compared with free biopolymer.

Example 7 — Spectral improvement by trityls

Three proteins (BSA, β -casein and ADH) were digested with trypsin and the resulting peptides analysed by MALDI-TOF mass spectrometry with or without derivatisation. The number of peptides identified for each protein is shown below. The theoretical total number of peptides that would be produced by trypsin digestion of each protein was calculated *in silico* and is shown in the second column the table below.

Protein	Number of theoretical peptides ⁺	Total number of peptides identified		MASCOT search score*	
		Underivatised	Derivatised	Underivatised	Derivatised
BSA	144	14 (10%)	41 (28%)	132	126
β -casein	27	4 (15%)	13 (48%)	no match	123
ADH	60	7 (12%)	18 (30%)	77	111

+ The number of theoretical peptides for each protein was generated assuming one missed cleavage and disregarding di- and mono-amino acids generated.

* Score is $-10 \cdot \log(P)$, where P is the probability that the observed match is a random event. Protein scores greater than 63 are significant ($p < 0.05$).

Derivatisation of peptides with trityl groups of the invention thus improves detection, as a significantly larger number of peptides was detected for each of the three proteins when derivatisation was used. Furthermore, protein identification by mass fingerprinting can be improved.

Taking β -casein as an example, the number of detectable fragments more than tripled, and the derivatised spectrum allowed a MASCOT-based identification which was not previously possible.

Example 8 — BSA fragmentation and mass spectrometry

Bovine serum albumin (BSA) was digested with trypsin and analysed by MALDI-TOF. The resulting spectrum is shown in Figure 8A. The experiment was repeated, but the peptide mixture was labelled with a dimethoxytrityl label after trypsin digestion. The spectrum in Figure 8B shows the dramatic increase in visible ions due to the trityl label. Four specific peptides have been highlighted in both spectra.

Example 9 — Mass spectrometry of amines


A solution of NHS-activated 4,4'-dimethoxy-4"-carboxyethyl trityl (0.1M) in THF/dioxane (1:1) was mixed with a solution (0.5-1M) of an amine or of a mixture of amines (for example, propyl amine, butyl amine, pentyl amine, hexyl amine and phenethyl amine), typically 10 ml of a solution of an activated trityl with 5 ml of an amine solution. The mixtures were purified on prep-TLC (2mm-thick

glass plates with UV254 indicator, Analtech/Aldrich-Sigma), typically in chloroform with 0.5% triethylamine. The areas containing the desired products were scratched off the plate, and the conjugates or the mixtures thereof were eluted using same solvent with 2-5% MeOH, filtered through a layer of glass wool, evaporated and dried. Figure 9 shows a spectrum obtained in this way.

- 5 It will be understood that the invention is described above by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.


CLAIMS

1. A method of forming an ion of formula (I):




comprising the steps of:

- 5 (i) reacting a compound of the formula (IIa):



with a biopolymer, B_P , having at least one group capable of reacting with M to form a covalent linkage, to provide a biopolymer derivative of the formula (IIIa):



- 10 (ii) cleaving the $C-X$ bond between X and the α -carbon atom of the derivative of formula (IIIa) to form the ion of formula (I);

where:

C^\star is a carbon atom bearing a single positive charge or a single negative charge;

X is a group capable of being cleaved from the α -carbon atom to form an ion of formula (I);

- 15 M is independently a group capable of reacting with B_P to form the covalent linkage;

$B_{P'}$ is independently the biopolymer residue of B_P produced on formation of the covalent linkage;

M' is independently the residue of M produced on formation of the covalent linkage;

Ar^1 is independently an aromatic group or an aromatic group substituted with one or more A ;

- 20 Ar^2 is independently an aromatic group or an aromatic group substituted with one or more A ;

optionally wherein (a) two or three of the groups Ar^1 and Ar^2 are linked together by one or more L^5 , where L^5 is independently a single bond or a linker atom or group; and/or (b) two or three of the groups Ar^1 and Ar^2 together form an aromatic group or an aromatic group substituted with one or more A ;

- 25 A is independently a substituent;

L_M is independently a single bond or a linker atom or group;


$n = 0, 1$ or 2 and $m = 1, 2$, or 3 , provided the sum of $n+m = 3$;

p independently $= 1$ or more; and


q independently = 1 or more.

2. A method of forming an ion of formula (I), comprising the steps of:

(i) reacting a compound of the formula (IIb):



with a biopolymer, B_P, having at least one group capable of reacting with M to form a covalent linkage, to provide a biopolymer derivative of the formula (IIIb):



dissociating X★ from the derivative of formula (IIIb), to form the ion of formula (I);

10 where:

X★ is a counter-ion to C★;

and C★, M, B_P', M', Ar¹, Ar², L_M, n, m, p and q are as defined in claim 1.

3. A biopolymer derivative of the formula (IIIa).

4. A biopolymer derivative of the formula (IIIb).




5. An ion of formula (I).

6. A compound of the formula (IIa).




7. A compound of the formula (IIb).

8. A method of forming an ion of formula (I) comprising the steps of:

(i) reacting a solid support of formula (IVai), (IVaii), or (IVaiii):



with a biopolymer, B_P, having at least one group capable of reacting with M to form a covalent linkage, to provide a modified solid support of the formula (Vai), (Vaii), or (Vaiii), respectively:



and either:

- 10 (ia) for modified solid supports of formula (Vai) cleaving the C-S_S bond between the α-carbon atom of the modified solid support of formula (Vai) and the solid support S_S to form the ion of formula (I);

(iib) for modified solid supports of formula (Vaii), either simultaneously or sequentially, cleaving the C-X bond between X and the α -carbon atom and cleaving the SS- -Ar1 bond between the solid support and the Ar1 group to form the ion of formula (I); or

(iic) for modified solid supports of formula (Vaiii), either simultaneously or sequentially, cleaving the C-X bond between X and the α -carbon atom and cleaving the SS- -Ar2 bond between the solid support and the Ar2 group to form the ion of formula (I);

where:

X, Ar¹, Ar², B_P¹, L_M, M, M', n, m, p and q are as defined in claim 1;

S_S is a solid support;



10 C---S_S comprises a cleavable bond between C and S_S;

S_S---Ar¹ comprises a cleavable bond between Ar¹ and S_S; and


S_S---Ar² comprises a cleavable bond between Ar² and S_S.

9. A method of forming an ion of formula (I) comprising the steps of:


15 (i) reacting a solid support of formula (IVbii) or (IVbiii):



with a biopolymer, B_P, having at least one group capable of reacting with M to form a covalent linkage, to provide a modified solid support of the formula (Vbii) or (Vbiii), respectively:



20



and either:



(ia) for modified solid supports of formula (Vbii), either simultaneously or sequentially, dissociating $\text{X}\star$ from the derivative of formula (Vbii) and cleaving the $\text{S}_\text{S} - \text{Ar}^1$ bond between the solid support and the Ar^1 group to form an ion of formula (I); or

(iib) for modified solid supports of formula (Vbiii), either simultaneously or sequentially, dissociating $\text{X}\star$ from the derivative of formula (Vbiii) and cleaving the $\text{S}_\text{S} - \text{Ar}^2$ bond between the solid support and the Ar^2 group to form an ion of formula (I);



where: $\text{X}\star$, Ar^1 , Ar^2 , B_P' , L_M , M , M' , n , m , p , q , S_S , $\text{C} - \text{S}_\text{S}$, $\text{S}_\text{S} - \text{Ar}^1$ and $\text{S}_\text{S} - \text{Ar}^2$ are as defined in claim 8.

10. A method of forming an ion of formula (I) comprising the steps of:

(i) reacting a solid support of formula (IVaiv) or (IVbiv):



with a biopolymer, B_P , having at least one group capable of reacting with M to form a covalent linkage, to provide a modified solid support of the formula (Vaiv) or (Vbiv), respectively:



and either:

(iia) for modified solid supports of formula (Vaiv), cleaving the C-X bond
5 between X and the α -carbon atom to form the ion of formula (I); or

(iib) for modified solid supports of formula (Vbiv), dissociating $X\star$ from the
derivative of formula (Vbiv) to form the ion of formula (I);

where:

X, $X\star$, Ar^1 , Ar^2 , B_p^i , L_M , M, M^i , p, q, n, m, and S_S are as defined in claims 8 and 9;

10 $M''-S_S$ comprises a bond between M'' and S_S ; and

M'' is the same as M except that S_S is bound to a portion of M which does not form part of
 M^i .

11. A solid support of the formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv).

15

12. A modified solid support of the formula (Vai), (Vaii), (Vaiii), (Vaiv), (Vbii), (Vbiii) or
(Vbiv).

13. A method of any of claims 8-10 or a product of claim 11 or 12 wherein the biopolymer is a
20 synthetic biopolymer.

14. A method or product of claim 13 wherein the synthetic biopolymer is an oligonucleotide, a
peptide or a carbohydrate.

15. A method for analysing a biopolymer, B_P, comprising the steps of:

(i) reacting the biopolymer B_P with a compound of formula (IIa) or (IIb) or a solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv);

(ii) providing an ion of formula (I); and

5 (iii) analysing the ion of formula (I) by mass spectrometry.

16. In a method for analysing a biopolymer, B_P, the improvement consisting of: (i) reacting a biopolymer, B_P with a compound of formula (IIa) or (IIb) or a solid support of formula (IVai), (IVaii), (IVaiii), (IVaiv), (IVbii), (IVbiii) or (IVbiv); (ii) providing an ion of formula (I); and (iii)
10 analysing the ion by mass spectrometry.

17. A method of claim 15 or claim 16 wherein the analysis by mass spectrometry is carried out in a spectrometer which is suitable for MALDI-TOF spectrometry.

15 18. A method of any of claims 1, 2, 8-10 or 13-17 or a product of any of claims 3-7, 11 or 12, wherein C★ bears a single positive charge, such that the ions of formulae (I), (IIb) and (IIIb) have the structures:

Formula (I)	$(Ar^2)_n - \overset{\oplus}{C} - [Ar^1 - (L_M - \{M' - B_P'\}_p)_q]_m$
Formula (IIb)	$(Ar^2)_n - \overset{\oplus}{C} - [Ar^1 - (L_M - \{M\}_p)_q]_m$ X^\ominus
Formula (IIIb)	$(Ar^2)_n - \overset{\oplus}{C} - [Ar^1 - (L_M - \{M' - B_P'\}_p)_q]_m$ X^\ominus

19. A method of any of claims 1, 2, 8-10 or 13-18 or a product of any of claims 3-7, 11, 12 or 18
20 wherein n = 2 and m = 1.


20. A method of any of claims 1, 2, 8-10 or 13-19 or a product of any of claims 3-7, 11, 12, 18 or 19 wherein p = 1, 2 or 3.

25 21. A method of any of claims 1, 2, 8-10 or 13-20 or a product of any of claims 3-7, 11, 12 or 18-20 wherein p = 1.

22. A method of any of claims 1, 2, 8-10 or 13-21 or a product of any of claims 3-7, 11, 12 or 18-21 wherein $q = 1, 2$ or 3 .

5 23. A method of any of claims 1, 2, 8-10 or 13-22 or a product of any of claims 3-7, 11, 12 or 18-22 wherein $q = 1$.

24. A method of any of claims 1, 2, 8-10 or 13-23 or a product of any of claims 3-7, 11, 12 or 18-23 wherein $n = 2$, $m = 1$, $p = 1$ and $q = 1$, such that the ion of formula (I) has the structure:



10


25. A method of any of claims 1, 2, 8-10 or 13-24 or a product of any of claims 3-7, 11, 12 or 18-24 wherein the biopolymer is a polymer found in biological samples.

15 26. A method or product of claim 25 wherein the biopolymer is a polypeptide, polysaccharide, or polynucleotide.

27. A method or product of claim 26 wherein the biopolymer is a polypeptide.

20 28. A method or product of any of claims 25-27 wherein the biopolymer does not readily form a molecular ion on illumination of laser light at 340 nm.

29. A method of any of claims 1, 2, 8-10 or 13-28 or a product of any of claims 3-7, 11, 12 or 18-28 wherein the ratio $m(\text{B}_P') / m(\text{IX})$ is more than 2, where $m(\text{IX})$ is the mass of the fragment (IX)



25 of the cation of formula (I) and $m(\text{B}_P')$ is the mass of the biopolymer residue B_P' .

30. A method of any of claims 1, 2, 8-10 or 13-29 or a product of any of claims 3-7, 11, 12 or 18-29 wherein M is: $-\text{NR}_2$; $-\text{SR}$; $-\text{OR}$; $-\text{B}(\text{R})\text{Y}$; $-\text{BY}_2$; $-\text{C}(\text{R})_2\text{Y}$; $-\text{C}(\text{R})\text{Y}_2$; $-\text{CY}_3$; $-\text{C}(=\text{Z})\text{Y}$;

-Z-C(=Z)Y; -C(=Z)R; -C(R)(OH)OR; -C(R)(OR)₂; -S(=O)Y; -Z-S(=O)Y; -S(=O)₂Y; -Z-S(=O)₂Y; -S(=O)₃Y; -Z-S(=O)₃Y; -P(=Z)(ZR)Y; -P(=Z)Y₂; -Z-P(=Z)(ZR)Y; -Z-P(=Z)Y₂; -P(=Z)(R)Y; -Z-P(=Z)(R)Y; or -N=C(=Z), where Y is independently a leaving group, Z is independently O, S or N(R) and R is independently H, C₁₋₈hydrocarbyl or C₁₋₈hydrocarbyl substituted with one or more A.


5

31. A method of any of claims 1, 2, 8-10 or 13-29 or a product of any of claims 3-7, 11, 12 or 18-29 wherein M is: -N(R)-; -S-; -O-; -B(Y)-; -C(R)(Y)-; -CY₂-; -C(=O)-; -C(OH)(OR)-; or -C(OR)₂-, where Y is independently a leaving group and R is independently H, C₁₋₈hydrocarbyl or C₁₋₈hydrocarbyl substituted with one or more A.

10

32. A method of any of claims 1, 2, 8-10 or 13-29 or a product of any of claims 3-7, 11, 12 or 18-29 wherein M is: $\text{---}\overset{\text{I}}{\underset{\text{I}}{\text{C}}}(\text{Y})\text{---}$, where Y is a leaving group.

33. A method of any of claims 1, 2, 8-10 or 13-29 or a product of any of claims 3-7, 11, 12 or 15 18-29 wherein the covalent linkage is selected from those produced through the reaction of one the



following groups: -CO-NH-; biotin-(strept)avidin; ; or -NH-CS-NH-.

34. A method of any of claims 1, 2, 8-10 or 13-33 or a product of any of claims 3-7, 11, 12 or 18-33 wherein L_M is O or S.

20

35. A method of any of claims 1, 2, 8-10 or 13-33 or a product of any of claims 3-7, 11, 12 or 18-33 wherein L_M is -E^M-, -(D^M)_t-, -(E^M-D^M)_t-, -(D^M-E^M)_t-, -E^M-(D^M-E^M)_t- or -D^M-(E^M-D^M)_t- (in the orientation Ar¹-(L_M{M}_p)_q or Ar¹-(L_M{M'}_p)_q, as appropriate),

where:

25 a sufficient number of linking covalent bonds, in addition to the covalent bonds at the chain termini shown, are provided on groups E^M and D^M for linking the p instances of M (or M') groups;

D^M is independently C₁₋₈hydrocarbylene or C₁₋₈hydrocarbylene substituted with one or more A;

E^M (in the orientation Ar¹-(L_M{M}_p)_q or Ar¹-(L_M{M'}_p)_q, as appropriate) is independently -Z^M-, -C(=Z^M)-, -Z^MC(=Z^M)-, -C(=Z^M)Z^M-, -Z^MC(=Z^M)Z^M-, -S(=O)-, -Z^MS(=O)-, -S(=O)Z^M-,

t = 1 or more.

5


36. A method of any of claims 1, 8, 10 or 13-35 or a product of any of claims 3, 6, 11, 12 or 18-35 wherein the group X is halogen, hydroxy, C₁₋₈hydrocarbyloxy, C₁₋₈hydrocarbyloxy substituted with one or more A, C₁₋₈heterohydrocarbyloxy, C₁₋₈heterohydrocarbyloxy substituted with one or more A, mesyl, tosyl, pentafluorophenyl, -O-succinimidyl -S-succinimidyl, or phenyloxy substituted with one or more A.

10

37. A method of any of claims 1, 2, 8-10 or 13-36 or a product of any of claims 3-7, 11, 12 or 18-36 wherein Ar² is independently cyclopropyl, cyclopropyl substituted with one or more A, aryl, aryl substituted with one or more A, heteroaryl, or heteroaryl substituted with one or more A.

15

38. A method of any of claims 1, 2, 8-10 or 13-37 or a product of any of claims 3-7, 11, 12 or 18-37 wherein Ar² is




or

39. A method of any of claims 1, 2, 8-10 or 13-38 or a product of any of claims 3-7, 11, 12 or 18-38 wherein Ar^1 is independently cyclopropylene, cyclopropylene substituted with one or more A, arylene, arylene substituted with one or more A, heteroarylene, or heteroarylene substituted with one or more A.

5

40. A method of any of claims 1, 2, 8-10 or 13-39 or a product of any of claims 3-7, 11, 12 or



41. A method of any of claims 1, 2, 8-10 or 13-40 or a product of any of claims 3-7, 11, 12 or 18-40 wherein L^5 is O or S.


42. A method of any of claims 1, 2, 8-10 or 13-40 or a product of any of claims 3-7, 11, 12 or 18-40 wherein L^5 is $-E^5-$, $-(D^5)_{t'}-$, $-(E^5-D^5)_{t'}-$, $-(D^5-E^5)_{t'}-$, $-E^5-(D^5-E^5)_{t'}-$ or $-D^5-(E^5-D^5)_{t'}-$,

where:

15 D^5 is independently C_{1-8} hydrocarbylene or C_{1-8} hydrocarbylene substituted with one or more A;

E^5 is independently $-Z^5-$, $-C(=Z^5)-$, $-Z^5C(=Z^5)-$, $-C(=Z^5)Z^5-$, $-Z^5C(=Z^5)Z^5-$, $-S(=O)-$, $-Z^5S(=O)-$, $-S(=O)Z^5-$, $-Z^5S(=O)Z^5-$, $-S(=O)_2-$, $-Z^5S(=O)_2-$, $-S(=O)_2Z^5-$, $-Z^5S(=O)_2Z^5-$, where Z^5 is independently O, S or $N(R^5)$ and where R^5 is independently H, C_{1-8} hydrocarbyl or C_{1-8} hydrocarbyl substituted with one or more A; and

$t' = 1$ or more.


Figure 1**Trityl Tagging**

AFG, activated functional group, i.e. NHS or maleimido

FG, functional group, i.e. NH_2 or SH

W, a bond between AFG and FG

(Bio)molecule, a molecule to be analysed, i.e. a peptide

Figure 2**Trityl Enhancer Tagging on Solid Support**

AFG, activated functional group, i.e. NHS or maleimido

FG, functional group, i.e. NH_2 or SH

W, a bond between AFG and FG

(Bio)molecule, a molecule to be analysed, i.e. a peptide



Figure 3**Reverse Trityl Enhancer Tagging on Solid Support**


Figure 4**Trityl Enhancer Tagging on Solid Support 2**

AFG, activated functional group, i.e. NHS or maleimido

FG, functional group, i.e. NH_2 or SH

W, a bond between AFG and FG

(Bio)molecule, a molecule to be analysed, i.e. a peptide

Figure 5**Solid Support-Assisted Trityl Enhancer Tagging**

6/15

Figure 6




Figure 7





Figure 9



7/15

Figure 8

Figure 8A




Figure 8B




Figure 10A




Figure 10B




Figure 11A




Figure 11B











Figure 12A






Figure 12B

14/15

Figure 13





Figure 14



PCT/GB2004/005140



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.